Podcasts about Kensington Gardens

Hace 125 años se escribió la historia de un niño que no quería crecer y buscó refugio en el país de Nunca Jamás. Peter Pan fue primero una obra de teatro del autor escocés J. M. Barrie (1860-1937) en Londres, que convirtió luego en libro en 1904 como "Peter y Wendy", siendo luego inmortalizada por los dibujos de Disney y tantas otras versiones cinematográficas, antes y después. El país de Nunca Jamás podría estar al otro lado del estanque londinense que en Kensington Gardens se conoce como The Long Water Serpentine, donde está la estatua de Peter Pan desde 1912 . Pero la isla no está allí en realidad, sino en la imaginación de muchos niños, aunque sólo algunos logren volar hasta allá. ¿Cómo se llega hasta allí? Según Peter Pan, siguiendo "la segunda estrella a la derecha, y luego todo seguido hasta la mañana". Bueno, en realidad allí no se llega, sino que es la isla la que te encuentra. Por lo menos a los personajes de esta historia, "la propia isla estaba buscándolos"... En este programa de radio "Al Trasluz", escuchamos fragmentos del libro, leído por Eugenio Barona, escenas de la película animada de Disney en 1953, la historia del escritor encarnado por Johnny Depp y la madre de los niños reales, interpretada por Kate Winslet en "Descubriendo nunca jamás" del director suizo-alemán Marc Foster en 2004 y la malograda recreación de Steven Spielberg en "Hook" (1992). Las canciones son de Dani Martín con El Canto del Loco (Peter Pan) en 2021 y Taylor Swift (Peter) en 2024. El texto y la narración de José de Segovia tiene como fondo instrumental, las bandas sonoras de John Williams para "Hook", la de James Newton-Howard para la poco memorable versión con actores de Disney en 2023 y la de Jan A P. Kaczmarek para "Descubriendo nunca jamás". La realización técnica y el diseño sonoro es de Daniel Panduro.

Noelle's birthday episode AND a Special Session?! Double specialness!! And that's why we thought it was time to talk about every literary inspiration behind Taylor's lyrics. Grab your tea and let's dive into some bookish parallels!

Do The Dead Appear At Noon? In the leafy paths of Kensington Gardens, where Victorian ladies take their morning walks, one woman feels an impossible touch. Not in darkness, but in searching daylight. Not with terror, but with recognition that defies reason. Someone watches her from behind curtained windows, measuring time with a doctor's patience. Family ties can bind or strangle, and some kinds of protection leave no visible trace. Wilkie Collins crafts a story where morning sunshine holds more mysteries than midnight, where what cannot be seen might prove more solid than shadow, and where the line between protection and possession blurs in the space between heartbeats. Take a while out of your busy day and listen to "Mrs. Zant and the Ghost," where daylight offers no refuge from what waits beyond the veil Learn more about your ad choices. Visit megaphone.fm/adchoices

Lucia Pietroiusti is the Head of Ecologies at the Serpentine in London and the first guest of Season Two of the Ecosystem Member podcast. If you aren't familiar with the Serpentine, it is a contemporary art gallery in Kensington Gardens. And better yet, admission to the galleries is free for all visitors making it incredibly accessible. Lucia is one of the driving forces behind the Serpentine's work as a curator, programmer and organizational strategist. As the Head of Ecologies, she works at the intersection of art, ecology and systems. Her role is to embed environmental responsibility throughout the Serpentine's infrastructure, operations, networks and programming. She also happened to create this role out of the General Ecology project we discuss in the episode that she started in 2018. However, her influence stretches beyond the bounds of Kensington Gardens. She was the curator for the Golden Lion-winning opera performance ‘Sun & Sea' at the Lithuanian Pavilion at the 58th Venice Biennale and the ‘Songs for the Changing Seasons' exhibition at Vienna's first Climate Biennale earlier this year. After you listen to the episode, make sure to check out her website that is linked in the show notes because this is just the tip of the iceberg of her work. If you aren't subscribed to our Substack, you can also visit ecosystemmember.com to check out a post with photos and videos of many of the projects we talk about in the episode. We're going to try to do a bit more with the Substack this Season to help you learn more about our guests and amazing art around the world, so make sure to subscribe. Huge thanks for everyone who is tuning in and if you enjoy this episode, please make sure to leave us a five-star review of Spotify, Apple Podcasts or give this episode a thumbs up on YouTube. Those a key signals to the platforms that this content is interesting and valuable and helps it become more discoverable to other potential listeners. And it helps us keep attracting great guests like Lucia. Links Lucia Pietroiusti Website Lucia Pietroiusti on Instagram ‘Sun & Sea' ‘Songs for the Changing Seasons' Infinite Ecologies Marathon at Serpentine General Ecology at Serpentine

Comic Reviews: DC o        Absolute Power: Task Force VII 7 by Dan Watters, Fran Galan o        Batman: The Long Halloween – The Last Halloween 1 by Jeph Loeb, Eduardo Risso, Dave Stewart o        Lobo Cancellation Special by Kyle Starks, Kyle Hotz, Dan Brown Marvel o        Avengers Annual 2024 by Derek Landy, Salvador Larroca, Guru eFX o        Venom War: Daredevil 1 by Chris Condon, Lan Medina, Yen Nitro o        Marvel Unlimited §  Jeff Week by Gustavo Duarte §  Alligator Loki 40 by Alyssa Wong, Robert Quinn §  Lovable Lockheed 4 by Nathan Stockman Boom o        Mighty Morphin Power Rangers/Usagi Yojimbo 1 by Ryan Parrott, Shawn Daley, James Fenner Dark Horse o        Magic Order Five 1 by Mark Millar, Matteo Buffagni, Giovanna Niro o        Masters of the Universe/TMNT: Turtles of Grayskull 1 by Tim Seeley, Freddie Williams II, Andrew Dalhouse o        Survival Street: The Radical Left 1 by James Asmus, Jim Festante, Abylay Kussainov, Ellie Wright DSTLRY o        Missionary 1 by Ryan Stegman, Jason Howard IDW o        My Little Pony: The Storm of Zephyr Heights 1 by Jeremy Whitley, Andy Price, Heather Breckel Image o        Creepshow Volume Three 1 by Chip Zdarsky, Kagan McLeod, James Stokoe o        Knights vs. Samurai 1 by David Dastmalchian, Fede Mele, Ulises Arreola o        Manchurian (Horizon Experiment) 1 by Pornsak Pichetshote, Terry Dodson, Rachel Dodson o        Old Dog Operations 1 by Declan Shalvey; PJ Holden, John McCrea, Mike Spicer; Declan Shalvey, Matias Bergara, Sofie Dodgson; Rory McConville, David O'Sullivan; Sumeyye Kesgin; Declan Shalvey, Luke Sparrow, Dee Cunniffe; Leonardo Romero, Triona Farrell; Alex Paknadel, Chris Sprouse, Dexter Vines; Charles Soule, Gavin Guidry, Chris O'Halloran o        Violator 1 by Marc Andreyko, Piotr Kowalski, Brad Simpson o        Violent Flowers 1 by Maria Llovet Mad Cave o        Revolution 9 1 by Mark London, Carlos Reno, Jao Canola Valiant by o        Black, White, and Bloodshot 1 by Luciano Saracino, Ariel Olivetti; Marc Guggenheim, Agustin Alessio; Matts, Guillermo Fajardo; Tim Seeley, Rodrigo Rocha Magma o        Hell's Half Acre 1 by Denton Tipton, Jack Jadson Indie o        Yuletide Flame by Hayden Fryer OGN Countdown o        Transplants by Dave Collard, Domenico Carbone, Josh Rodriguez o        Grinch Takes a Vacation by Kaeti Vandorn o        New Adventure of Turning Red Vol 2: Panda Power by Sloane Leong, Sergio Algozzino, Sara Galanti o        Moosicians by Steve Behling, Jeff Crowther o        Inventor Vol 2: The Secret of the Scrap Goblin by Lars Henrik Eriksen o        A Quick and Easy Guide to Coming Out by Kristin Russo, Ravi Teixeira o        Spinal Cord by David Brana, Pahito o        Peter Pan in Kensington Gardens o        Amazing Grapes by Jules Feiffer o        Holler by Jeremy Massie Additional Reviews: Wild Robot, Justice League International, Wilderness, Agatha All Along ep3, Penguin ep2 News: rumors of a James Gunn/Jim Lee Superman comic in 2025, Justice League x Sonic, Hellboy: Crooked Man going straight to digital, superhero trademark Trailers: Sinners, Caddo Lake, Dream Productions, Killer Cakes, Sweatpea Comics Countdown (25 September 2024): 1.     Helen of Wyndhorn 5 by Tom King, Bilquis Evely, Mat Lopes 2.     Spectregraph 3 by James Tynion IV, Christian Ward 3.     Ultimate Spider-Man 9 by Jonathan Hickman, Marco Checchetto, Matt Wilson 4.     Lobo Cancellation Special by Kyle Starks, Kyle Hotz, Dan Brown 5.     Action Comics 1069 by Gail Simone, Eddy Barrows, Danny Miki, Jonas Trindade, Rex Lokus 6.     Standstill 2 by Lee Loughridge, Andrew Robinson 7.     Drawing Blood 6 by David Avallone, Kevin Eastman, Troy Little, Ben Bishop, Luis Antonio Delgado 8.     Detective Comics 1089 by Dan Watters, Ram V, Guillem March, Christopher Mitten, Luis Guerrero, Triona Farrell 9.     Batman: Brave and the Bold 17 by Michael Conrad, Christopher Mitten, Miguel Mendonca, Mike Spicer; Zipporah Smith, Mike Norton, John Kalisz; Alex Segura, Andy MacDonald, Patricio Delpeche; Troy Peteri, David Baldeon, Veronica Gandini 10.  Universal Monsters: Frankenstein 2 by Michael Walsh  

ENJOYING A NEW CHALLENGE. Minsuk Cho is the South Korean architect who has envisioned the Serpentine Pavilion 2024, the 23rd pavilion in the series, in London's Kensington Gardens. It is titled Archipelagic Void as a unique void surrounded by a constellation of smaller adaptable structures, each of which has a specific purpose: the Gallery, the Auditorium, the Library, the Play Tower and the Tea House. Minsuk Cho trained in Seoul and New York, and worked in America and the Netherlands before returning to Korea to open his own practice, which he calls Mass Studies. “Architecture's unique language allows people to interact, engage and understand in a very positive way.“ “This Serpentine project is exciting because the whole thing only takes six months from conception to completion.“ “The world is changing, and I don't want to become a jaded professional. I take everything as a new challenge.“

During the Second World War, Bushy Park was home to a sprawling military base. This is where General Dwight D. Eisenhower came to work on a top-secret plan called ‘Operation Overlord'.  On 6 June 1944, after months of preparation, the plan was ready – 156,000 Allied troops invaded Normandy, some landing on the beaches and others arriving by air. Now known as D-Day, this event ultimately led to the defeat of Nazi Germany.  And so much of it was planned right here in the park. Listen on to learn more about this amazing piece of history. Support the Show.Support the show: https://www.royalparks.org.uk/supportAbout The Royal Parks: The Royal Parks is the charity that exists to make sure London's eight historic royal parks will always be there to enrich the lives of local residents and visitors to London. The charity looks after eight of London's largest open spaces: Hyde Park, The Green Park, Richmond Park, Greenwich Park, St James's Park, Bushy Park, The Regent's Park and Primrose Hill, and Kensington Gardens. For more information visit www.royalparks.org.uk Follow The Royal Parks on X (14) The Royal Parks (@theroyalparks) / X, Facebook.com/TheRoyalParksLondon and Instagram.com/TheRoyalParks

THE WHITE RAT KILLER - not really something that I expected to consume my whole week. Sherlock had reason to suspect that a particular townhouse in Kensington Gardens was not all it seemed. We followed his curiosity to the next logical point and it was there where I saw a truly chilling sight. For ad-free, early access to adventures in full go to www.patreon.com/sherlockandco Follow me @DocJWatsonMD or get in touch via email docjwatsonmd@gmail.com Listener discretion is advised. This podcast is property of Goalhanger Podcasts. Copyright 2024. ------- SHERLOCK AND CO. Based on the works of Sir Arthur Conan Doyle Paul Waggott as Dr. John Watson Harry Attwell as Sherlock Holmes John Brannoch as Wiggins Rayner Bourton as Professor Orson Presbury Additional voices : Nutthawat C Joel Emery Adam Jarrell  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Support our Podcasts: https://libri-vox.org/donate In both the play and the novel, Peter often visits the "real world" of London to listen in on bedtime stories told by Mary Darling to her children. One night, Peter is spotted, and while trying to escape, he loses his shadow. On returning to claim his shadow, he wakes Mary's daughter, Wendy Darling. When Wendy succeeds in re-attaching his shadow to him, Peter takes a fancy to her and invites her to Neverland to be a mother to his gang of Lost Boys, the children who are lost in Kensington Gardens. Wendy agrees, and her brothers John and Michael go along. The dangerous and magical flight to Neverland is followed by many adventures. --- Support this podcast: https://podcasters.spotify.com/pod/show/librivox1/support

"In the end she grew up of her own free will a day quicker than other girls." Sally and her neighbour discuss tree spirits and magical bracelets on her narrowboat. As the rains draw in, Sally settles down to read J. M. Barrie's Peter Pan. She thinks about clouds and feelings, listens to chamber music, and follows the story of Peter Pan from Kensington Gardens to Rustington-on-Sea. Our feelings have always been with us, like the weather. And on rainy days, it's good to dance more.  Miss Cull, a frequent guest on the podcast, can also be found in Sally's latest book, The Green Lady, available from all good booksellers.  Original music, ‘Wednesday', by Paul Clarke.  Special thanks to Andrew Smith, Violet Henderson, Kris Dyer, and Maeve Magnus. For Laetitia. 

Paul and Rob take a turn round Hyde Park and Kensington Gardens after a very hot weekend of running. Featuring cancelled marathons, breaking weather, Rob's Great North Run, Paul's LSR, when runs are shorter than they seem, cormorants in Hyde Park, the Tonkinson memorial in Kensington Gardens, Rob's chest pains, Paul's palace, final training and taper plans ahead of the Yorkshire Marathon, Rob's son heading off to University, international disasters, the legal firm of Barnet and Finchley, running in the Royal Parks, poor air quality at Paul's Dad's house, Mo's last race, embracing change as an ageing runner, tough gigs in posh hotels, stare-y-eyed travellers, food and drink report... and more.Thank you as ever for listening, for your support, and for sharing all your running adventures with us on line.SUBSCRIBE for early access, ad-free listening and more... and BUY OUR BOOKS; you can get Rob's book Running Tracks here - https://www.waterstones.com/book/running-tracks/rob-deering/9781800180444 - and you can get Paul's book 26.2 Miles to Happiness here: https://www.waterstones.com/book/26-2-miles-to-happiness/paul-tonkinson/9781472975270Happy running.Support this show http://supporter.acast.com/runningcommentary. Thanks for listening - we'll be back next week, and if you're desperate in the meantime, subscribe and become a Fan - there are hundreds of old episodes you can have a go on, AND you'll get next week's episode three days early. Happy running! https://plus.acast.com/s/runningcommentary. Hosted on Acast. See acast.com/privacy for more information.

In this episode, join our own Charlie Linton as he takes a walk in London's Hyde Park with one of the UK's most prominent young birdwatchers, Dr Mya-Rose Craig. Charlie and Mya-Rose visit some of the wetland and woodland habitats of the park to discover many of the wonderful birds that live and forage in the Royal Parks, and chat about all things bird and nature related.You can follow along the same route using our handy map with photos of the birds we spot. The route sticks to paths so is suitable for buggies and wheelchair users. The entire route is approximately 1.3 miles (2.1km).The activities of The Royal Parks' Help Nature Thrive project, including this podcast, have been made possible thanks to the support of the wonderful players of People's Postcode Lottery. Dr Mya-Rose Craig can be found at https://www.birdgirluk.com/Support the showSupport the show: https://www.royalparks.org.uk/supportAbout The Royal Parks: The Royal Parks is the charity that exists to make sure London's eight historic royal parks will always be there to enrich the lives of local residents and visitors to London. The charity looks after eight of London's largest open spaces: Hyde Park, The Green Park, Richmond Park, Greenwich Park, St James's Park, Bushy Park, The Regent's Park and Primrose Hill, and Kensington Gardens. For more information visit www.royalparks.org.uk Follow The Royal Parks on Twitter @theroyalparks, Facebook.com/TheRoyalParksLondon and Instagram.com/TheRoyalParks

In this video filmed in Kensington Gardens on 23rd May 2023 Michael and Geetha were having a general discussion about identification. ----more---- This episode can also be watched as a video here and a more compressed audio copy in Opus format (which can be listened to in the VLC media player and some other apps) can be downloaded from here.

In this video filmed in Kensington Gardens on 23rd May 2023 Michael answers the following two questions asked by Geetha: ----more---- "Verses 942 and 943 of Guru Vācaka Kōvai talk about severance of the knot. Does severance of the knot indicate the complete destruction of the ego?" and: "In verse B19 of Guru Vācaka Kōvai [verse 16 of Upadēśa Taṉippākkaḷ], Bhagavan writes: ‘The state of sleep in waking will result by subtle investigation, in which one always examines [or keenly attends to] oneself. Until sleep shines blending in waking [and] in dream, incessantly perform that subtle investigation'. Does severance of the knot described in verses 942 and 943 result in wakeful sleep, or does enquiry continue beyond that until it results in wakeful sleep?" This episode can also be watched as a video here and a more compressed audio copy in Opus format (which can be listened to in the VLC media player and some other apps) can be downloaded from here.

In this video filmed in Kensington Gardens on 23rd May 2023 Michael answers the following questions asked by Geetha: ----more---- "You defined grace beautifully in one of your talks the other day when you said ‘grace is the act of attention being pulled inwards'. This is sometimes very perceptive and sometimes not. How does one open oneself up to grace so as to be pulled inwards constantly? Or is this happening all the time, and we are sometimes aware of it and at other times not?" and: "How can one develop sufficient love to turn within so that one prioritises self-attention over everything else?" This episode can also be watched as a video here and a more compressed audio copy in Opus format (which can be listened to in the VLC media player and some other apps) can be downloaded from here.  

Sarah's in London in garden & flower heaven, and recorded a quick lowdown of her visit so far - Kensington Gardens,  Royal Botanic Gardens at Kew, and the RHS Chelsea Flower Show! 

In this episode join Anna Barry and Scott Smith live from St James's Park as they bring you all the highlights of the big day. They speak with those coming to the park to view the action, describe the Coronation Procession and chat with The Household Cavalry Museum and Commanding Officer of The King's Troop, Royal Horse Artillery.Support the showSupport the show: https://www.royalparks.org.uk/supportAbout The Royal Parks: The Royal Parks is the charity that exists to make sure London's eight historic royal parks will always be there to enrich the lives of local residents and visitors to London. The charity looks after eight of London's largest open spaces: Hyde Park, The Green Park, Richmond Park, Greenwich Park, St James's Park, Bushy Park, The Regent's Park and Primrose Hill, and Kensington Gardens. For more information visit www.royalparks.org.uk Follow The Royal Parks on Twitter @theroyalparks, Facebook.com/TheRoyalParksLondon and Instagram.com/TheRoyalParks

In this episode we explore what it takes to prepare the Royal Parks for events like the Coronation. We hear how it feels to have the eyes of the world on your work and learn how we make the parks look their best all year round. We also take you on a virtual walk down the grand processional route that is The Mall - pointing out items of interest along the way.Support the showSupport the show: https://www.royalparks.org.uk/supportAbout The Royal Parks: The Royal Parks is the charity that exists to make sure London's eight historic royal parks will always be there to enrich the lives of local residents and visitors to London. The charity looks after eight of London's largest open spaces: Hyde Park, The Green Park, Richmond Park, Greenwich Park, St James's Park, Bushy Park, The Regent's Park and Primrose Hill, and Kensington Gardens. For more information visit www.royalparks.org.uk Follow The Royal Parks on Twitter @theroyalparks, Facebook.com/TheRoyalParksLondon and Instagram.com/TheRoyalParks

This time we're looking back at previous Coronations, exploring how the parks have been involved in these over the centuries – and we also chat to someone who attended the last Coronation in 1953.Support the showSupport the show: https://www.royalparks.org.uk/supportAbout The Royal Parks: The Royal Parks is the charity that exists to make sure London's eight historic royal parks will always be there to enrich the lives of local residents and visitors to London. The charity looks after eight of London's largest open spaces: Hyde Park, The Green Park, Richmond Park, Greenwich Park, St James's Park, Bushy Park, The Regent's Park and Primrose Hill, and Kensington Gardens. For more information visit www.royalparks.org.uk Follow The Royal Parks on Twitter @theroyalparks, Facebook.com/TheRoyalParksLondon and Instagram.com/TheRoyalParks

Join Anna Barry and Scott Smith as they explore the history and tradition of coronations in the parks – past and present.Support the showSupport the show: https://www.royalparks.org.uk/supportAbout The Royal Parks: The Royal Parks is the charity that exists to make sure London's eight historic royal parks will always be there to enrich the lives of local residents and visitors to London. The charity looks after eight of London's largest open spaces: Hyde Park, The Green Park, Richmond Park, Greenwich Park, St James's Park, Bushy Park, The Regent's Park and Primrose Hill, and Kensington Gardens. For more information visit www.royalparks.org.uk Follow The Royal Parks on Twitter @theroyalparks, Facebook.com/TheRoyalParksLondon and Instagram.com/TheRoyalParks

This week we are headed back to the garden to finish out the tale of peter pan

This week we are getting all Victorian with a little Peter Pan origin story

Stopped at the children's playground and walked around the grounds. Found a pub for supper and walked back

He's here, he's there; Dr. Hillman brings drug safety everywhere! So given the rules and regulations he needs to follow, the title “vigilante” could be nothing but ironic.We chart David's progress through choosing pharmacology as a subject to study, and settling on pharmacovigilance as a career to pursue. Listen: The Bollywood beats come courtesy of Cambridge-based artist Anish Kumar whose music you can also find on Bandcamp: anishkumarmusic.bandcamp.com, YouTube, Instagram and Twitter.Watch:Subscribe to our YouTube channel now for all future recordings. Episode transcript[Background intro music playing is "Nazia" by Anish Kumar]Parmvir: Hello everyone. And welcome to another episode of the 2Scientists podcast, where inspiring scientists share their work with you, wherever you like to listen. Today we come to you from a rather unique spot, rather than a cafe or bar we are camped out in Kensington Gardens in London, because it's a glorious day and our podcasting equipment allows us to do that. But enough about me and us, we are here today, of course I am your host Parmvir Bahia here and we're here with David Basanta, but we also have with us another David who is very special to me, he is an old friend of mine from my PhD program, and we shared much time and much swearing over experiments together at University college London. How are you David Hillman? David: I'm doing well. Thank you. It's, as you say, it's a, it's a lovely day and, it's nice to be back with old friends. Parmvir: Yes, yes. Of course everything rotates background to COVID and whereas we would normally see each other once a year. It's been three, four, possibly? David: Three, I think that's yeah.Parmvir: Miserable. David: Yeah. Sad times we shall have to make up for it. Parmvir: We will, we will. There's a bottle of Cava with our name on it. Once we've done with this. David: And onion rings. Parmvir: And onion rings. Yes. Fancy Marks and Spencer's one's though. So let's start at the beginning. I'm not talking about like, where were you born kind of thing. Although you can mention Kidderminster if you'd like. So as I understand it, we had a relatively similar track as undergraduates. So you did a bachelor's in pharmacology, correct? David: Yeah, that's right. Parmvir: So tell us why, why pharmacology? David: So this is gonna age me, age us.So I, for my A levels, so for my senior school exams, I, studied chemistry, biology, and maths, and I wanted to study something at university that combined chemistry and biology. And so this is the bit that will age us. So back in the day, if you remember, you would go to the, career advice department who were trying to help people to steer people towards what options they might want to pick at university.And they had this huge telephone directory effectively, which, mapped together people's different, combinations of A level courses and then gave you a list of options that you could, study at university. So I was sat in this little tiny room with this career advisor person, and they were basically running through this list of different courses.And when they came to pharmacology, they'd already mentioned pharmacy, which, you know, most people know what it is, but then they said pharmacology and I stopped them and said, well, what's, what's the difference? And they actually gave a pretty good summary. They said, it's more the biology of medicine. It's more the, the research and development of new medicines. They said it's potentially a controversial topic because it's the pharmaceutical industry is itself sometimes controversial and there's other aspects to the industry, which are, challenging sometimes. But yeah, that's how it started. So I picked a few different pharmacology courses, one of which was King's College London. I was always very practical, so I liked the idea of doing a year in industry at some point. So I chose a sandwich course like you and yeah, so that took me to KCL all that time ago. Parmvir: Mm. So I didn't realize how similar our tracks had been, because I also did biology, chemistry and maths, and I wanted to do something with the chemistry and the biology.And I got put in that direction by David: did you pick it out of the phone book as well? Parmvir: I did. What was it called? There was a name for it. David: It was pretty like a UCAS publication. Parmvir: Yes. It was just, it was enormous. David: Yeah. Parmvir: But yeah, in any case, I also, I did a sandwich year and I got to go and hang out in Germany for a year, which was fun.But yeah. So obviously after that you came to do a PhD at UCL where we were, well, I was a year ahead of you, I think. David: Yeah. You were. Parmvir: Why? Why did you do a PhD? David: So well for the reasons that I guess a lot of people do them, which is that I wasn't sure what to do next [both laugh] and a PhD seemed like a good way to string it out for another few years before I figured that out.But the reason I landed on UCL was that when I did go and do my year in industry, which like you was for a large pharma company, I worked in a lab looking at some non-clinical safety models. And we were using electrophysiology techniques at the time that was sharp electrode electrophysiology.Parmvir: You're gonna have to explain what electrophysiology means. David: Oh, don't make me do that. It's been 20 years [Parmvir laughs]. Oh, it's basically where you take either isolated cells or tissues and you put tiny, tiny electrodes into them and measure the changing currents across cell membranes. And as you put different drugs on, you can look at different effects of those drugs how they affect the electrical signals that you can measure.And really it's ions moving back and forward across membranes by little things called ion channels. So yeah, so I'd done sharp electrode electrophysiology there. I went back to university to finish my last year, and then the question came up about what to pick for a PhD. And I thought, well, although I hadn't enjoyed electrophysiology, it's something that I had started to, I guess, gain an interest in. Plus I had some skills that in that area. So, yeah, so I found a course, rather a PhD studentship at UCL, which seemed to fit the bill. It was looking at using a slightly different electrophysiology technique, so patch, clamping in a different area, but I thought it was something that I could use what I'd learnt in my year in industry Parmvir: I gave you some of these questions beforehand. David: Yes, because I'm incapable of spontaneous reaction to questions [Parmvir laughs]. Parmvir: Actually, I loved it so much that I have to read out your description of what your memory is like. David: I was quite proud of that. I coined that yesterday. I used to think of my memory as a lobster pot. Parmvir: All right. So you said I've just come up with a good analogy for my recall memory. It's like a reference library. You have to put in a request and then go away for a bit. When you come back, I'll have retrieved something from the vaults. Hopefully. David: Yeah, exactly. Parmvir: But aside from that I wanted to say this might be something of a loaded question, but what did you think of your PhD experience?David: You know, I really, I look back on those years with fond memory. Now it's partly because looking back, you edit out all of the stress and anxiety associated with doing a research project like that. I remember at the time when I first started UCL ran some induction courses where they pulled together PhD students and other postgraduate students from all sorts of backgrounds and John Foreman who you'll remember who was the Dean of students at the time, he gave a little introduction to UCL, but also gave some interesting advice let's say and pointers.And one of the things he pointed out in that session was the high degree of mental illness that is encountered by students in general taking these types of courses because they are stressful. And you often feel like you are kind of on your own. Driving your own research project forward. Sometimes through difficult times. So I do remember that in particular, but you know, what I remember mostly is just how impressed I was with all of the people that surrounded me because our department was not particularly flashy in its kind of presentation, but there were some seriously impressive people there.So I always like to think of our lab in the sense of, you know, it was run by effectively by Dennis and, and Guy when we got there. But before then it had been run by Don and before then it had been run by Bernard Katz who was a Nobel laureate. So it felt like we were the either grandchildren or great grandchildren of a Nobel Laureate and the whole department was a bit like that. It had a lot of very understated people who were world experts in their, in their field. And I always felt like the dumbest person in the department. But that didn't bother me too much because you know, being surrounded by all this greatness and even just, you know, the little glimpses of things you would see at the kind of coffee breaks and in the corridors, some of those memories still live with me, you know. Bearing in mind, this was back in what, between 2001 and 2005.So very, very early days of smartphones, things like trios and things like that, which seem antiquated now. But I remember coming across two old professors, so probably in their seventies or eighties comparing their smartphones and that like little microcosm, are the things that I loved about the department.Parmvir: Actually, I mean, I think you're, you're definitely selling yourself short. Like nobody would say that you weren't smart enough to be there. And I think one of the things that kind of ties into the, the mental health aspect is that we all felt that way. David: Yeah. Parmvir: Except we didn't express it to anyone else. It's, it's utterly ridiculous. How can we all be the least smart person in the room that's just not possible. David: Yeah. Parmvir: And after that, we all got our PhDs anyway, so, you know yeah. David: I certainly have no regrets about it. And I look back on those times with, with very fond memories, for sure. Parmvir: Yeah. Just talk briefly about what you did for your project and what the difficulties were.David: So the lab that I joined, so which, which you were a part of as well, their specialty was calcium activated potassium channels. And over time, the lab had looked at these ion channels in various different settings. The project that I was given was looking at these channels in vascular endothelial cells, which was a cell type that no one in the lab had ever studied before.Parmvir: Mm. David: So one of the biggest challenges that we were hit with straight away was that no one in the lab could really help that much with firsthand experience of how to obtain these cells, how to isolate them, how to culture them, how to grow them and really how to manage those cell types. So you might well remember that, the first, probably nine months of my PhD was just spent trying to culture these cells. Parmvir: Mm-hmm David: and it started with you know, available tissue from rats and other small mammals.But then eventually we were not having success with culturing cells from those models. So I switched onto pigs and, you know, I'd done a bit of reading that, you know, these vessels, because they were much larger the blood vessels, it was easier effectively to culture cells from, so I looked in the phone book and I found the address of an abattoir out in the middle of Essex.And there began my weekly trip for getting on for two and a half years to the deepest, darkest corners of Essex to go and retrieve pig, coronary artery cells once a week. Parmvir: Yeah. And essentially you suffered because these things were so flat. [David laughs] And when you're trying to, so you, for anyone who's listening, you have to picture trying to get a very, very fine tube onto something that is incredibly flat, and essentially you need this thing to form a vacuum seal and that just wasn't gonna happen. David: No, so, you know, vascular endothelial cells, they're the cells that line blood vessels, which is why they're, they're very flat. They're like tiles almost on the inside of veins and arteries.And you know, with other cells in the lab that were being looked at like the ones that you were looking at, like DRGs and like neurons and things like that, you know, you were basically putting the, the electrode down onto like a ball. Parmvir: Yeah. David: So the gap between the bottom of the dish and the top of the cell was who knows, 10, 20 microns, something like that. The cells that we were looking at, they flattened themselves out so much, they were about one micron, I think we estimated and therefore the tiniest vibration in the room would destroy the cell. And yeah, so the first stage was trying to culture, the damn things, and that was extremely challenging. It took a long time, but nine months of the way through managed it, and then began the whole pain of trying to get electrical recordings from them, which turned out to be as difficult. Parmvir: Yeah. So one of the things, I don't know if we ever talked about this, but what did you aspire to do after you'd done your PhD originally?Like, did you have any kind of idea? David: I mean, I think I was always headed into the pharmaceutical industry, which is where I landed up. In my undergrad degree in, I think my either first or second year, I did a very nice course, which was a kind of practical introduction to the pharmaceutical industry and from very top level, how drugs are developed and how pharma companies are organized internally and how the research progresses. And that, I'd always found that interesting. I mean, I find the entire pharmaceutical industry absolutely fascinating. And still do to this day. It's such an amazingly complex industry. And so, yeah, so I think I'd always been heading in that direction. Sure enough, the PhD certainly made me decide I was done with bench science [Parmvir laughs]. So, you know, by the time you've spent three plus years plodding along with these experiments that have a success rate of one in 50 sometimes. Parmvir: Yeah. David: You know, days and weeks without getting any data, and towards the end, still being in the lab at three o'clock in the morning, trying to get something to work and breaking more and more glassware as time goes on [Parmvir laughs]Yeah, I decided I was done with bench science, although I loved being in the labs, I loved playing in the labs. But I was never that into the kind of reading of the scientific papers and that sort of thing. Once it came down to maths and things like that, I wasn't so engaged. I needed to see practical things. Parmvir: Yeah. I feel like at some point we realized we were both some kind of engineer at heart rather than David: Yeah. Maybe Parmvir: scientist, David: maybe. Parmvir: It's more like, how does this work rather than trying to answer a bigger scientific question. David: Yeah. Parmvir: But obviously you were, you were a little bit scarred by your experience there, and you ended up going off in, I guess, a very different track from what the standard academic education leads you towards. So I think at this point this might be a good place to put your disclaimer in. David: Yes. So I work in the pharmaceutical industry and over time I've worked for, and with a variety of different companies.Any of the content that I describe today are my opinions and my opinions alone, and often they're really based off things which are in the public domain. In fact it's all based off things that were in the public domain and also some of the education that I've received, because actually, even after I finished my PhD, I then years later went on to study a, another academic course specifically in pharmacovigilance and pharmacoepidemiology.Parmvir: Oh, where did you do that? David: London school of Hygiene and Tropical Medicine. Parmvir: Oh. David: And it's interesting because it's a short course and I felt was a very valuable course. It's a course where regulatory authorities also send their people to learn too. Parmvir: So there's a lot of questions I can ask next.But one of the things that your job description throws up is this word "pharmacovigilance". What does that mean? David: Okay. So somewhere because I'm not gonna do it justice from memory, I'm going to read out the WHO definition of pharmacovigilance. It doesn't roll off the tongue, unfortunately, which is why it's never quite there in my head.So per the WHO: pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects, or any other medicine, or vaccine-related problem. So essentially it is the process and the science relating to drug side effects. Now as you'll remember from pharmacology days, very early on, you're taught that all pharmacologically active substances, if it applies to the human body have side effects. The same side effects are not encountered by every person.And you know, some of the side effects might have obvious clinical manifestations. Some might not, you might get side effects, never know you've had them. And of course they vary massively in severity. So when you are looking at a medicine, particularly one that you're introducing to kind of general use in humans, you have a trade-off to make because you have an expected therapeutic benefit, but you also have to be mindful of potential side effects, particularly serious side effects and how much tolerance you have for those versus the good that the drug is supposed to do.And achieving that balance is one of the big challenges that's faced in drug development.Parmvir: So what you do really, it kind of comes at the end of the whole process of clinical trials and so on for given products, right? David: It actually starts right at the beginning of clinical development.So. Parmvir: Oh, hang on, I have to ask David's question: does that make you a Pharmacovigilante? David: [David and Parmvir laugh] I've often wondered the same thing myself. But yeah, so pharmacovigilance takes off really where toxicology leaves. So before you can put a drug into clinical development, by which I mean development in humans, drugs first have to go through preclinical development and that's where all the various toxicology studies are run.Parmvir: Can you quickly define toxicology for us? David: Sure. It is really focusing on the well, the potentially toxic side of medicines. So before you put a drug anywhere near a human, you want to be absolutely certain that it doesn't cause various catastrophic side effects in humans.So, for example, you need to be confident that it doesn't cause cancer. You need to be confident that it's not gonna cause a heart attack immediately, or cause a stroke immediately or things like that. So as per regulations in pretty much every country in the world, before you put a drug anywhere near a human in a clinical trial, it has to go through a standard set of tests.And there's various ways to achieve that. You know, sometimes those are tests using computer simulated models. Sometimes they are using individual cells or cultured cells or tissues. And sometimes as is well known in the industry they're using animal models and these are legally required tests.So every drug that goes through the process has to go through these. So that's done before it gets to clinical development. And then you start with phase one clinical trials which are studies on, usually on healthy volunteers and they're very small trials. They involve perhaps a few tens of patients. And the only purpose of those trials is to look at the safety and tolerability of the drug. So this is the first time you're putting the drug into humans. There is a bit of an exception to that. So although these are usually conducted on healthy volunteers, for some drugs, including, for example oncology drugs. Those drugs are usually along the more kind of toxic end of agents, so it's not ethical to put those into healthy volunteers. So sometimes those studies are conducted in a patient population. So once a drug moves into human studies into phase one, from that point, really for the rest of the lifetime of that drug as a human medicine pharmacovigilance is involved. So all the way through the phase one, two and three studies and then once the drug goes onto the market, pharmacovigilance continues.So the companies or the pharmaceutical or biotech companies that are developing these assets have a legal requirement to collect and analyze this data on an ongoing basis pretty much forever. Until that drug is eventually, perhaps if it's lucky enough to get to the market, until it's withdrawn from the market, perhaps many decades later.Parmvir: Very good. And I think that there are probably some very topical things that have come up recently as a result of COVID 19, which is important to consider when we're talking about these things, in that we are not just relying on these clinical trials that have gone out to ensure that these things are safe, but once they're out there that you have to continue to get feedback from people who are taking these to ensure that they continue to be safe in the long term, right?David: That's true. So, you know, ordinarily in clinical development, once you get through phase 1, 2, 3, and if you are lucky enough to have a drug, which is sufficiently efficacious, tolerable to go to market, then yes, you know, the drug's released to market and you continue to monitor for this stuff.Vaccines are in a particularly special category because they are drugs that are given to healthy people. Mm yes. And so therefore the benefit risk balance is more complicated in some ways, because , you know, it's, it's hard to consider the benefit to the individual of taking a product when they don't yet have that disease.So now there are other drugs that are in a similar category, other drugs that are given to healthy people. This is where I can ask you some questions. So what, what do you think those other drugs include? Parmvir: Oh, goodness. Um, I'm trying to think off the top of my head, what they might be. David: Yeah. It's very unfair. Parmvir: All I can think of at the moment are the other vaccines. David: Okay. So, Parmvir: but there are lots of prophylactic things. Yeah. Yeah. I can't think of anything David: Contraceptives. Parmvir: The obvious prophylactic. Yes. David: Drugs used for travel. So things like anti-malaria tablets. Parmvir: Oh yeah. David: Drugs used for things like smoking cessation Parmvir: mm-hmmDavid: stuff like that.So again, these are all drugs that are generally given to healthy people. So, you know, and this is where benefit risk balance comes into sharp focus, because if you have a drug that has been developed to treat a very hard to treat cancer, let's say, then when you consider benefit risk balance you know, if these patients are effectively going to die without a treatment, and this is the only treatment available, you might be able to accept that a drug has a one in a hundred chance of causing a fatal stroke. Particularly if that drug is given in hospital and these things can be, can be managed. If however, you are developing a cough medicine, then your tolerance for any type of dangerous side effects is basically zero, and of course, many drugs elsewhere on that scale. So yeah, benefit risk balance is a key part of what has to be looked at during drug development. And yeah, as we say, vaccines are particularly challenging. Often these days when a new drug is developed the clinical development and the studies don't stop necessarily when the drug is released for marketing. So, often as a condition of the marketing authorizations that are granted for these drugs, there have to be continuing studies to look at safety. These are called post-authorization safety studies. And so there's ongoing collection of data in a rigorous way to keep monitoring for various things. Either new things that we didn't know about the drug before, because of course when you're in clinical development, your number of patients is normally quite small Parmvir: mm-hmm David: so you're less likely to spot very rare side effects. You wouldn't usually detect a one in 50,000 probability side effect in a clinical trial cohort. Parmvir: Yeah. David: But sometimes these post authorization safety studies allow you to pick up more of that and enable you to characterize some of the side effects that you do know about more in detail.Parmvir: Yeah. So David B here asks essentially how long do these things go on after the drug's been on the market? For example, is there still pharmacovigilance for aspirin? David: Yes. Every single drug that has a marketing authorization out there it is the law in pretty much every country in the world that all safety data that becomes available to the marketing authorization holders, that's the company that owns the rights to the drug and effectively sells the drug, they're required by law to collect process, analyze and report this data. Now as drugs age, the natural reporting rate for some of these drugs drops so the probability of a physician or a pharmacist or a nurse, or even a patient reporting a side effect probably drops over time because theses are not new medicines anymore, but even so, any data that is collected has to go through that process, which is the pharmacovigilance that we were referring to earlier. In addition to that, all companies with marketing authorizations have to look at scientific and medical literature. It all has to be reviewed, so in European requirements, including the UK on a weekly basis, companies have to trawl some of the big literature databases, such as PubMed and M base, they have to trawl that information for any articles on their drugs. And any indication of side effects or other similar challenges. Parmvir: So how is this information collected and processed? Cause you've said obviously doctors, nurses, patients, they will all report certain things. Mm-hmm how do you kind of get them to a central place and cataloged and how do you decide what are actual side effects versus David: So if we think about the front end of the process, most pharma companies out there will have medical information help lines. So these are help lines that are set out there so that healthcare professionals. So that's the physicians, the, the pharmacists, the nurses and others but also consumers can contact the company for more information about the medicine and also potentially report adverse events, side effects. In parallel to that the same thing's going on with the regulators. So in the UK, for example, we have the yellow card scheme, which these days is a web portal system where anyone can go in and report side effects of medicines they're taking. In the us, you have the MedWatch scheme, which is very similar. Most companies around the world have similar things. Plus you've also got ongoing clinical trials, clinical studies, so data is coming in that way too. We've got data coming in from literature that I've mentioned. The regulators, when they receive stuff directly, they often pass that information over to the pharma company.So essentially all this information is coming towards the pharma company. It all gets directed to a pharmacovigilance department. And then we go through the process of processing that data. And so that data comes in from everywhere around the world where the drug is available for patients to take both in clinical trials and on the market.So the process basically consists of firstly translating the data, if it needs to be translated that gets captured into a safety database and there are various commercial safe databases out there. This is where companies collate all the information received on their drugs. And it goes through a process whereby data is kind of standardized it's put into standard terminology in a way that is compatible with the regulatory requirements. A narrative is constructed. So we write a story of what's happened to the patient from beginning to end. We look at various things like if the information is available to us, you know, what other medications were the patients taking? What's their medical history? What was the sequence of events? So what was the time to onset if possible, if we have that information between the patient taking the drug and them reporting the side effect, what the clinical course of the side effect was, so did the patient recover? Was any adjustment made to the the, the dosing or any treatments given? And so all that gets written up, we then decide what other information do we need to know?And then there's a feedback loop to go and ask the reporter if they'll provide additional information. Usually we ask for more information on more serious adverse events. We don't wanna overburden the reporters. Now reporters in clinical trials, so physicians involved in those, they're legally obliged to help with that process. Spontaneous reporters that we refer to, which is just where any healthcare professional or consumer contacts, the company, that's a voluntary reporting system, so we can ask them for additional information, they don't have to provide it, but we have to ask the questions anyway. So the information gets pulled together. It then goes, usually goes through a medical review, so we have kind of scientists pulling the data together. And then we have physicians reviewing the case, making sure it makes medical sense. And then depending on the seriousness of the case and other attributes, that case might have to be reported out to regulators worldwide.And a lot of the reports which are serious, have to be reported out within 15 days of what we call day zero, which is the first day anyone in the company became aware of the report. Parmvir: Mm-hmm. David: But to give you an idea, the large pharma companies are dealing with potentially tens of thousands of reports a week that are coming in on all of their products. So these are vast systems that are set up and they have to be set up to be able to meet all of the regulatory requirements in terms of timelines, for reporting. So the data's coming in, the expedited reports are going out in the format that the regulators require. We also have to pull together what we call aggregate reports. So these aggregated analyses of data over time for newer drugs, for example, those are submitted in Europe every six months. And then over time as the drug gets older, the gap between reports gets longer. And then also we're doing something, what we call signal section, which is where we are analyzing the data. And we're looking for trends in the data. Where we think we've got patterns we're starting to then look into researching those patterns a little bit more, you know, if we start to see, for example that I don't know that we are getting what appears to be a disproportionate number of nose bleeds, let's say, in a patient cohort, we would, you know, do background research on, well, you know, is there a plausible biological mechanism that we know about through the development of the drug? Was there stuff seen in the animal studies or even the human studies that might indicate that there's a, there's a root cause here.We'll look into confounding effects. Are all these patients on other drugs, which actually are likely causing that? And yeah, so kind of an appraisal is done: what's going on? Is it likely to be caused by something else? And if not, you know, we, keep on looking and those conversations then have to be shared with the regulatory authorities.And over time, what you'll see is the labeling of the product, the professional labeling which in Europe, including the UK, is the SMPC, the summary of product characteristics, which is a bit like the instruction manual for the product, which is available to healthcare professionals and the simplified version of that PIL those little leaflets you find inside of packs, those eventually get revised on an ongoing basis to accommodate the new knowledge that we are gaining on the side effect profile of the drug. So this is an ongoing process and it happens throughout the entire lifetime of the, of the drug. Parmvir: But yeah, so here's a subject that no one's talked about for a little while. COVID 19 David: mm-hmm Parmvir: [laughs] Obviously I know there's probably a collective groan from people listening right now, but it seems like a relevant subject, given the conversations around safety that people are having with regard to the vaccine. So do you know if there's been like a major uptick in these reports by individuals, of side effects from the vaccines, or do you take account of the fact that so many billions of people essentially at this point have received at least one shot of the vaccine versus how many reports you get coming in?David: Yeah. So this is one of the big challenges, and one of the things I should have said about drugs like vaccines is because they're given to such vast numbers of people, it becomes a particular challenge to differentiate between things which are being caused potentially by the vaccine and other things, which unfortunately are just bad luck of being a human being.And by that, I mean, so years ago when I was doing one of the academic courses we were being taught about the vast amounts of research that had to be done in terms of epidemiology before the HPV vaccines were released. So these vaccines were being released for use in teenage girls, and at the time it was felt that there was perhaps an insufficient understanding of the general health of that population, including things like what is the probability of a freak occurrence that a teenage girl is going to have a stroke or something like that? Things which we think of as of course, they're exceptionally rare, but they do happen.Parmvir: Mm-hmm David: and I'm talking about in untreated populations. Parmvir: Yep. David: But of course, you know, some of these patients are also on birth control and things like that, that also have other risk factors associated with them so my understanding is before the HPV vaccines were released, a huge amount of epidemiology research was done so that when the new vaccines were released, we knew that we would expect, and I'm just gonna make up a number here that, you know, one in 500,000 teenage girls would have, I don't know, some kind of fatal event which would just naturally occur, you know, even without them having the vaccine. And so that's similar for other vaccine rollouts as well. There has to be a good understanding of the background events of other things that, people will have happen to them, which have nothing to do with the medicine that you are giving.So, you know, that data is kept available and kept an eye on by the regulatory authorities and also the pharma companies. We don't have background rates for everything, so being prepared for what might come and then, you know, there perhaps isn't so much panic when the first case comes in of a patient that has one of these catastrophic events but if you start to see more than that, that's when you start to perhaps get more interested in: is this really being caused by the vaccine or the drug of interest. So, yeah, a lot of upfront work has to be done before you even put the drug out there. I mean, in terms of the COVID vaccines and the treatments, because of the high degree of public interest and scrutiny a lot of these drugs when they were first given and the vaccines were first given, so adverse events, side effects were tracked through post-authorization safety studies. So actually a lot of people, when they got their first doses, consented to have maybe a follow up call from an investigator who would ask them about various side effects that happened. So in addition to all of the natural spontaneous reporting that was coming in, there were very large cohorts of past study data coming in which is a robust way to look at these things. I know as well, there were legitimate questions about, you know, the COVID vaccines in particular were produced fairly quickly compared to the usual 10 to 15 years in development of, of a product. But you know, there are various reasons for this. So vaccines are perhaps one of the medicines where it's more possible to template out the product and therefore switch out components. But they still have a product which is similar to other products that have previously been used. But also, the COVID era in terms of vaccine development and treatment development was, in my opinion at least a completely unique event in terms of drug development so far. If you think of drug development as a kind of universe, or I'm gonna use some wonky analogies here, but let's say as galaxies, which have solar systems within them that have planets within them.So if you think of the galaxy of drug development you have all of these different stakeholders involved. You have the pharmaceutical companies and biotech companies and the service companies that support them, that's one area. You have the regulatory authorities but you have many other stakeholders.You have patients, of course they're the most important. For chronic diseases you might have patient advocacy groups. But also, you know, you guys are part of this universe as well, because you are the ones doing basic research, which is the foundation on which all, you know, all of this is, is ultimately built. So you have universities and other research organizations. You have the funding bodies that sit behind those that decide where the research money goes. And then out the other end of the process you have ethics committees that are involved in approving clinical trials. You have payers. So these are the organizations that ultimately pay for medicinal products in the UK, for example, that's the NHS. Parmvir: Yep. David: In the US, that would be insurance companies. Parmvir: Yeah. David: You have many other stakeholders. So you have obviously healthcare professionals at the end of the day, new drugs have to be woven into the fabric of medicine. And so you have to bring HCPs along with you. There are the learning bodies as well in relation to HCPs, the kind of professional bodies.So that's really at a kind of galaxy level, these are all the different solar systems. And then within them, if you look at the pharmaceutical biotechnology and service provider solar system, within those you have an incredibly complicated set of different skills departments, functions, you have the functions that are doing discovery.So these are the early days of, development where, you know, biologists and chemists are working out, you know, what are the new therapeutic targets we can look at? Then you have the clinical development division. You have the patent divisions, you have the regulatory affairs functions. You have the pharmacovigilance functions. You have the medical affairs functions, you have the medical information functions [Parmvir cackles]. There are, and I'm going to miss out many, many. You have the, the bio stats folks, you have the medical writers. And then of course you have the manufacturing, which is in itself a completely different, you know, specialized world.So yeah, you're dealing with a very complicated process with lots of things which are interlinked. But for me, if you think of all these things, like if you use layout or different compass, let's say, and I'm talking about the compass you use to check direction, not the ones you used to draw circles [Parmvir laughs] and if you scatter them all out they'll all be pointing at different directions. You know, all of these different entities have their own priorities. Because of course the industry as a whole is developing many different medicinal products for different reasons. I think when COVID came along, it was like drawing a magnet across the top of all those compasses and it got all the needles to point in the same direction.So you had governments who had a clear incentive to try and support the development of treatments. So you had governments putting up money, which was perhaps slightly unusual. They were putting money into basic research, such as the type of stuff that you guys do. They were putting money into diagnostics, which are critical for things like COVID.They were putting money into the development of vaccines and into treatments. And then of course, you know, you have the pharma companies where there was a scramble to try and develop something, to help humanity in its hour of need. You had the regulators with a lot of focus on them you know, and everyone watching their, every move and trying to ensure that you know, as many processes that often might take months, or perhaps even years were made as efficient as possible.Parmvir: Mm-hmm David: And it was a unique point in time because everyone was lined up with the same objective. So it meant, for example, that, you know, parts of the industry, which are normally a nine to five job, became a 24/7 job. Parmvir: Yeah. David: For a short period of time.And there was a huge amount of collaboration, which happened between the different stakeholder groups, you know regulatory authorities offered perhaps free scientific advice to companies that were developing this stuff. They met very regularly with companies that were in development. They gave a lot of advice as to what their expectations were when the data was received by them. They shortened some administrative pathways let's say which usually take a lot of time. They prioritized resource. So there's resource specifically waiting for this data to come in. And so, yeah, a lot of normal processes were adapted so that things could be done as efficiently as possible.And the outcome was that, you know, these drugs went through the entire process in a much more efficient way than would usually be encountered. I think another thing as well is with things like vaccines, the side effects that we anticipate to see, including the rare unusual ones ordinarily these manifest within, you know, days or weeks.It's not something that usually we anticipate things to occur years later. So there was that aspect too, but yeah, it was a, it was a unique time. Parmvir: Yeah. And actually this is a good throwback to Dr. Carina Rodriguez's podcast because she ran one of the clinical trials for the vaccine in children at USF where I work.David: Oh, fascinating. Parmvir: Yeah, so she talked about some of the things that you mentioned as well. David: I should say I was not involved sadly in any of the COVID vaccine development, but you know, it was fascinating to watch and actually to see my profession become a talking point in the news every day. Parmvir: Yes. David: It was very interesting to see all of this play out.Parmvir: Yeah. So actually, that's probably a good point to pause and ask you, what do you actually do? David: Okay. So [everyone laughs]. So as I've kind of indicated the process of pulling in adverse event data of coding it, which is the term we use for tidying up all of the data, putting it into a safety database, writing those narratives, getting the medical review, getting the important cases out the other end to the regulators, writing the reports, doing the signal section.These are very complicated processes and every company will develop them slightly differently. You know, small biotech companies, they might only have one product. It might only be approved in one or two countries. A top five pharma company will have hundreds of products authorized in many countries around the world. But all of these processes are put together in compliance with extremely strict regulations. Regulations that as I said exist in almost every country in the world and actually the regulations kind of cross over in the sense of, if you have a product that's authorized for marketing in the UK and the US, for example you know, the UK requires you to collect all the data and analyze it as does the US.They also require you to collect the data from each other's territories so companies are in the middle of the very complicated regulatory framework, which is a little bit different in each country, but fortunately is harmonized through some international bodies and international terminology. But building pharmacovigilance systems is complicated and it has to be done right. Firstly, for the obvious reason that we want to protect patients it's in no one's interest that that that patients are not protected. But also, you know, the penalties for not complying with these complex regulatory requirements are severe. And so my job really, as a, let's say senior leader within a pharmacovigilance department is to make sure that we build the right structures.And for these companies that we that we keep an eye out on all the areas, which are potential challenges and that companies are being compliant with the legislation to which we're all held. And so, so yeah, so building pharmacovigilance systems, I think is the simplest way I can describe it.Parmvir: It sounds pretty heavy and pretty complicated. David: Yeah. I mean, if you look at the larger pharma companies, if you add up all of the resource that they put into pharmacovigilance that they're legally required to put into pharmacovigilance, to service the needs of their products. A lot of things are outsourced these days, if you the count everything that comes from the outsourcing organizations as well, the big pharma companies have thousands of people like me involved in the processing and analysis of this data. So it is a big area, and that is all we do. You know, we are not involved in any other aspect of the drug. Not involved in the sales and marketing, for example, with the product, that's almost the complete opposite side of the company to us, all we do is you know, work in this very professionalized, very standardized discipline, which is pharmacovigilance. Parmvir: So David has a couple of questions. So first one should be relatively quick, which is that, is there a regulatory authority that is the gold standard? David: [David laughs] This is a very politically sensitive one.There are certainly some regulatory authorities who, particularly in some of the larger markets who are let's say more prominent. So examples would be the US FDA, the food and drug administration that is the drug regulatory authority for the United States. In the UK, we also have an extremely prominent regulator, the MHRA they're one of the oldest regulators, I believe in the world. So that's the UK medicines and healthcare products, regulatory agency. But you know, every country has its own regulator and whilst there are some who put themselves out there, perhaps as world leading regulators, there are just as many others that are doing the same important job for their countries. The European Union and European Economic Area has a slightly more complicated system because they have a coordinating regulatory authority, which is the European Medicines agency, the EMA, who many of you all have heard about in news reports, particularly during the COVID situation. But at a national level, you also have all of the national regulators who are working in tandem with the EMA. Parmvir: Okay. So this sounds quite different from, obviously it's very different from what you were doing during your PhD. David: Yes. Parmvir: He also wants to know, how did your PhD work, prepare you to do what you do now. David: If I could sum it up in one phrase, and this is a phrase which is overused, but I think in this case, it is really true: problem solving.Parmvir: Mm-hmm David: because it's interesting, you mentioned earlier that you and I we're almost engineers. Well, I went from becoming a physical engineer, at least in a lab environment to a process engineer. And, you know, I always used to think very naively when I was doing the basic research with you, I used to think, look, we are solving problems that no one knows the answer to. This must be the hardest job in the world. [Parmvir laughs] We're not solving manmade problems. Manmade problems must be so easy to solve. But no manmade problems [Parmvir laughs] are also particularly challenging. And when I say manmade problems, you know, I'm not talking about problems that someone is deliberately created, it's just, you know, logistical challenges, and just the challenges caused by working in, you know, different regulatory envionments with different sets of requirements and how to build processes that meet all of the requirements at the same time. And react to events, of course, because it might well be that you've had a product that has been ticking along nicely for a long time. And then suddenly there is a safety concern with the product. And if that safety concern is in the public domain, you will be deluged with reports in relation to that product called stimulated reporting. And you know, of course sometimes companies will be subject to class action lawsuits particularly in the US. So they might also receive large volumes of reports all in one go. All of those reports have to meet the same legal timelines, but now suddenly you've got 10,000 reports landed on your desk. Each one takes four hours to process and they're all due to the regulators in 15 days. So yeah, it is challenging working in a hyper regulated environment. Parmvir: Essentially these are problems that come about because we are humans. David: Exactly. Yeah. Parmvir: And we have to somehow live together. David: Yeah. Parmvir: So I had a couple of questions from my little sister and these might not be directly related to your work, but they are related to the fact that you work within an environment that involves clinical trials and patients and so on.And so Sukhy wants to know are side effects from drugs, usually the same for healthy people versus patients. David: This is a great question and cause me a little bit of head scratching. I think, I mean, the answer is it depends, I think by and large. Yes. But there will be some exceptions and those exceptions include things like some of the oncology treatments, because obviously there is an interaction often between the drug and the tumor, for example, so in a healthy person you can't emulate that because there is no tumor. So an example would be a phenomenon called tumorlysis syndrome which can only occur when there's a tumor to react to the particular drug. But by and large, yes, we extrapolate safety data from healthy individuals initially, which is why the earlier phases of studies are done often in healthy volunteers with some exceptions. But yeah. Then when we move on to phase two and then phase three, phase two and three are conducted in patients that have the indication of interest, I have the disease that we're trying to treat.Parmvir: So another question she had: how do you know people who are not healthy will be able to tolerate the drugs given that initially that they're tested on healthy people?David: So the first thing I would say is I'm not an expert in the design of clinical trials, but as I said, as you go through phase one which are the trials that are normally on healthy patients, you actually start out with a tiny, tiny dose. So you have an idea of dosing from your animal studies, but the data isn't always transferrable. But you take the maximum tolerable dose in animals, including in the most sensitive animals. And you then cut that by huge factor by perhaps 500 fold. Parmvir: Right. David: So you start out with a tiny amount and then you escalate up the doses to see how the patients are tolerating the drug, not the patients subject, I should say. So these are healthy volunteers usually. Parmvir: Yep. David: So that's phase one, but yeah, then of course, when you go into phase two, you're dealing with a different patient population. I don't know exactly how that's always done, but of course, you know, trials are put together by experts in the field. And they involve, you clinicians whose expertise is this particular area of medicine.Parmvir: Yeah. David: And of course it's not just the physicians at the pharmaceutical company and the biopharma company and the scientists, I should say as well. Also, this stuff is going to regulatory authorities, it's going to ethics committees, all of whom will have their own areas of expertise. So, you know, protocols are designed around the patient and to ensure the patients are not put at unnecessary risk.Parmvir: Ah, sometimes David sends me one of those questions that really makes me giggle. And this is if regulations are so important and onerous, how do I start my own biotech in the garage? David: [David laughs] Well, it's interesting, you know, companies don't necessarily have to be that big themselves to get started, but what they will need is a lot of help.Parmvir: Yeah. David: So what you'll see these days is you know, new biotechs starting up. But they rely very heavily on outsourcing. So they will partner with service providers with contract research organizations, with contract manufacturing organizations, all sorts of other parties that have the expertise that perhaps they aren't able to pull together themselves.But yeah, there are some companies out there, particularly smaller companies in earlier development that are, you know, pretty small might have 20 people in the company. Parmvir: Yeah. David: But they will need to rely on the help of many others, because going back to the kind of universe description that I gave, you know, there are so many specialized areas that you need to have covered in order to pull together everything you need, both to run a clinical trial. and also to submit a marketing authorization application. And then also keep your product compliant with all of the legal requirements that are out there.Parmvir: It's a lot.David: It is a lot, and you know this is why drug development is so costly because it needs a truly vast number of specialists involved. And, you know, quite a lot of physicians as well. And also, you know, most drugs that enter drug development don't make it all the way through the other end, so the end costs of medicinal products also have to cover the cost of the drugs that didn't make it.And plus companies only have a certain period of exclusivity before their drug becomes generic, i.e., other companies can start making it. Parmvir: So this is purely from a personal perspective, from your point of view: what do you think about the fact that obviously you have these companies who have put so much money developing these things, which were designed to treat a global pandemic. And yet we found that for example, like entire continents, like Africa still don't have a lot of people vaccinated against COVID 19, and those companies will refuse to open up the patents to allow them to be able to get people to stay healthy. David: Yeah, it's an area that really I'm not really sufficiently qualified to talk on. And I'm not just saying that, you know, through not wanting to put my foot in my mouth, but particularly with some of the vaccine technologies that were used, they were not simple medicines to manufacture. So not simple to manufacture, not simple to store, not simple to distribute. And sometimes I guess, it is perhaps a legitimate concern of a company that if other companies start making their same drug to a lower quality, that can have ramifications elsewhere. Now I'm not saying that that was the reason behind some of what you mentioned. Now there was a vaccine that was developed the UK vaccine which was specifically developed from the outset to be made available in developing world countries, let's say, and specifically to be made available at cost. And even the way that product was designed, it can be manufactured and stored at fridge temperature Parmvir: mm-hmm, which is a big deal. David: Exactly. It is a big deal, you know, those are all very important components to consider. A vaccine that could be used in those environments. But even, I remember because I vacuumed up all of the documentaries I think on television, Netflix, everywhere else about all of the challenges that were being faced. And, you know, there were even things that you just wouldn't think about, which was, you know, because the mRNA vaccines had to be stored at -80 [degrees Celsius], there wasn't enough minus 80 freezers in the developed countries, let alone figuring out how to develop and ship these to other countries with different climatic conditions.And so you even had the manufacturers of that type of equipment, having to up their game and suddenly churn out much more equipment than they previously had. So, yeah, there's no simple answer. I mean, historically there've been other challenges in the past with other types of drugs, such as the HIV medications. In the end access to those drugs was resolved through very careful dialogue between companies, regulators others. Access issues, I believe to those drugs, and again, this is just basically what I see on documentaries and other things; where are access problems these days, they're not in relation to the drug supply chain they're in relation to other things like people not wanting to come forward and receive treatment because of the stigma associated with things like that.Parmvir: So in short, do you enjoy your work? David: I do. I mean, I can honestly say that in my work every day is different. I'm very privileged in my job to support a number of different companies that are developing different products with a very wide variety of indications. And also, you know, just when you think you've seen it all worked with a wide variety of medicinal products, suddenly something completely new will come along. For example, we are now on the precipice of many commercial gene therapies coming out. Parmvir: Ooh. David: And you know, those products have some different considerations. Perhaps some of these interventions are irreversible Parmvir: mm-hmm.David: So, you know, what happens if patients do start developing something rare and unexpected. You have patients surviving a lot longer than was originally envisaged so, you know, are there other things which come about you know, as a result of the underlying disease that just no one had ever seen before. And yeah, many other types of technologies and the regulations are always having to evolve to take into account of these new therapies and the challenges associated with them.Parmvir: Well, it sounds like you will continue to live in interesting times. David: Yeah. I don't think I'm going anywhere anytime soon . Parmvir: Well, thank you so much for your time today, David. That was fantastic. And yeah, as I say, we kind of thought of you as soon as we started thinking about the safety surrounding things like COVID vaccines and knew that was your jam.So yes, we very much appreciate your time today. David: Okay. Thank you very much. [musical interlude]David: So I mentioned earlier that at an early point in my PhD, I switched to studying vascular endothelial cells that were harvested from pigs. So essentially these were pigs that were being slaughtered for the meat industry. And so I had to look through a phone book and identify an abattoir that I could go to and get the tissue that I needed to do my experiments so obviously this all had to start somewhere. So I put in a call to an abattoir in deepest, darkest Essex. And I gingerly made my way on the train to this place, which of course was in the middle of rural nowhere. And unfortunately the first day that I picked to go, it was snowing. Now we don't get vast amounts of snow in Southern England, but this was a decent sprinkling of snow. So I arrived in this quiet rural destination and I walked across various fields. I think I'd perhaps just got GPS on my phone, but it was very early days. And I was lost in fields of white in no time at all. So I ended up putting in a call to, the guys, to, come and pick me up, which they very kindly did. So then, you know, at that time I really didn't know what a coronary artery looked like so what I decided to do for that first trip was I just collected the fresh hearts that they were able to bring out the processing facility. So these were kind of warm pig hearts, freshly harvested from animals. I think I had three hearts or something like that. And so I had a large polystyrene box with me with some ice in it. And I think they were kind enough to give me the ice, as I put these hearts inside bags and put them in the box and then started making my way back to London. And of course, you know, this being a cold day, the heating was on, on the train, and so as I was sat on the train, in fact, I think it was when I got onto the tube, I suddenly became horrified that my polystyrene box was starting to leak water. And of course I knew, but no one else knew on the tube that within that water were bags, perhaps not secured, very tightly containing hearts and containing probably a fair amount of blood.And I suddenly started sweating that this puddle that was starting to pull around my polystyrene box on the floor of the tube would suddenly start to go pink and then red. And then before I knew it, I would be in serious trouble. So it was just one of those situations where the tube journey seemed to get longer and longer, and I was sweating more and more and then it got to the point where I felt that I couldn't wait any longer, so I kind of dashed outta the tube at the next station went up what was perhaps one of the longest escalators on the underground and managed to just get out the other side before I caused perhaps a fake terrorist incident or something like that. I was trying to think about how I would explain that I'd got three hearts in my polystyrene box and a set of scalpels bearing in mind that pig's hearts are very similar size to human hearts as well. So, yes, I managed just about to get to the lab. I clearly looked quite distressed, I suppose when I got back to the lab. So I started telling this story to my PhD supervisor, Dennis, and uh a retired professor that had come into the department, Don. And before too long, the two of them were crying with laughter at my story.So, um, so yeah, so that was my very first trip and yes, never, never forgotten.[musical outro]David: Our lab, when we first joined, it was quite old and a bit dog eared. And there was one particular chair in the office, which was, I mean, it was like a typical office swivel chair, but it had definitely seen better days and it was extremely uncomfortable. And when we had lab meetings, no one wanted to sit on this chair. And so Parmvir and I nicknamed it, Beelzebub's stool.

Friday arvo in the park. Show notes A Walk in Kensington Gardens by Dorothy Porter Silent co-producer K Elizabeth Morgan House Antonia Pont Dorothy Porter's The Bee Hut Ep 179. Solace & Trash Cary Tennis: All the practice you get makes you better David Ireland Brendan Casey & the Melbourne School of Continental Philosophy Bruce … Continue reading "Ep 200. Anti-insights"

See omnystudio.com/listener for privacy information.

Daniel Brettig, Mark Bickley, Darryl Webb, Sunday Dech, Cyril from Kensington Gardens, Terry McAuliffeSee omnystudio.com/listener for privacy information.

The 2022 Booker Prize Short List was announced at 7pm on Tuesday 6 September 2022 at the Serpentine Pavilion, Kensington Gardens, central London and RNIB Connect Radio's Toby Davey was there to capture the atmosphere and the announcement of the short listed books by Booker Prize chair Of Judges, Neil MacGregor. Just before the announcement of the short list, Toby caught up with Neil MacGregor to find out a bit more about the 2022 long list and how he and the rest of the Judges whittled down the 13 books to the six short listed books, plus also a bit about some of the Authors and the six chosen book clubs who will be each given one of the six short listed books to read and discuss. The winner of the 2022 Booker Prize will be announced at a ceremony on 16 October 2022 at the Roundhouse in London. More details about the Booker Prize and the short listed books can be found by visiting the Booker Prize website - https://thebookerprizes.com/ (Image shows RNIB logo. 'RNIB' written in black capital letters over a white background and underlined with a bold pink line, with the words 'See differently' underneath)

This episode we're talking about Literary Fan Fiction! We discuss ancient myths, fairy tales, Sherlock Holmes, copyright, Sherlock Holmes, authorized sequels, Sherlock Holmes, and sequels vs reinterpretations! Plus: Sherlock Holmes! (Okay, he didn't get mentioned that much.) You can download the podcast directly, find it on Libsyn, or get it through Apple Podcasts, Stitcher, Google Podcasts, or your favourite podcast delivery system. In this episode Anna Ferri | Meghan Whyte | Matthew Murray | Jam Edwards Things We Read (or tried to…) The Girl in Red by Christina Henry The Strange Case of the Alchemist's Daughter by Theodora Goss Rappaccini's Daughter by Nathaniel Hawthorne was reprinted in Evil Roots: Killer Tales of the Botanical Gothic Wide Sargasso Sea by Jean Rhys Jane Eyre by Charlotte Brontë Lost Boi by Sassafras Lowrey Peter Pan in Kensington Gardens by J. M. Barrie (Wikipedia) Peter and Wendy by J. M. Barrie (Wikipedia) Copyright status Telling Tales by Patience Agbabi The Canterbury Tales by Geoffrey Chaucer Other Media We Mentioned The House of Silk by Anthony Horowitz And Another Thing… by Eoin Colfer Shadow Master Series Volume 3 by Andy Helfer, Kyle Baker, and Joe Orlando Includes the comic in which The Shadow's head is placed on a robot body A Night in the Lonesome October by Roger Zelazny Jack the Ripper in fiction (Wikipedia) (Yes, there's an entire article and it mentions at least five additional stories that feature Sherlock Holmes.) The Ballad of Black Tom by Victor LaValle The League of Extraordinary Gentlemen by Alan Moore and Kevin O'Neill Fables (comics) by Bill Willingham (Wikipedia) The Argonauts and the Quest for the Golden Fleece (Wikipedia) Beowulf (Wikipedia) Pride and Prejudice and Zombies by Seth Grahame-Smith and  Jane Austen Grendel by John Gardner Fifty Shades of Grey by E. L. James The Murder of Mr. Wickham by Claudia Gray The Other Bennet Sister by Janice Hadlow A Study in Emerald by Neil Gaiman (Wikipedia) A Study in Charlotte by Brittany Cavallaro The Great Mouse Detective (Wikipedia) Sherlock Holmes in the 22nd Century (Wikipedia) Elementary, Dear Data (Wikipedia) - Star Trek: The Next Generation episode House (TV series) (Wikipedia) Elementary (TV series) (Wikipedia) Sherlock (TV series) (Wikipedia) Dorian Gray (2009 film) (Wikipedia) Victor Frankenstein (film) (Wikipedia) The Adventures of Shirley Holmes (Wikipedia) Enola Holmes (film) (Wikipedia) Holmes on the Range by Steve Hockensmith (Actually just about cowboys who really like Sherlock Holmes) Sherlock Holmes: Adventures in the American West by John S. Fitzpatrick Links, Articles, and Things Fan fiction (Wikipedia) Matthew was probably combining Robert Ludlum (died in 2001 and since then thirty books have been published under the “Ludlum brand”) and Tom Clancy (died in 2013 and since then 18 books have been published under the “Clancy brand”) Marple: Twelve New Mysteries A 2022 collection of new stories by various authors about Agatha Christie's Miss Marple character Cthulhu Mythos in popular culture (Wikipedia) Robin McKinley (Wikipedia) Frankenstein's monster (Wikipedia) How Rocket Raccoon Rescued My Brother, Famed Marvel Writer Bill Mantlo by Mike Mantlo Doujinshi (Wikipedia) Doraemon Doujinshi Accused of Infringing Copyright Hark Podcast Sherlock Holmes  (Wikipedia) Sherlock Holmes and the Case of the Copyrightable Character by Nicholas Perrotti Sargasso Sea (Wikipedia) 22 “Literary Fan Fiction” (retellings, adaptations, sequels, parallel novels, etc.) books by BIPOC (Black, Indigenous, and People of Colour) Authors Every month Book Club for Masochists: A Readers' Advisory Podcasts chooses a genre at random and we read and discuss books from that genre. We also put together book lists for each episode/genre that feature works by BIPOC (Black, Indigenous, & People of Colour) authors. All of the lists can be found here. For this booklist, the original story being retold/referenced appears (in parentheses). Telling Tales by Patience Agbabi (Canterbury Tales by Geoffrey Chaucer) The Adventures of China Iron by Gabriela Cabezón Cámara (El Gaucho Martín Fierro by José Hernández) The Family Chao by Lan Samantha Chang (The Brothers Karamazov by Fyodor Dostoevsky) Windward Heights by Maryse Condé (Wuthering Heights by Emily Brontë) The Meursault Investigation by Kamel Daoud (The Stranger by Albert Camus) Unmarriageable by Soniah Kamal (Pride and Prejudice by Jane Austen) Sex and Vanity by Kevin Kwan (A Room With a View by E.M. Forster) The Ballad of Black Tom by Victor LaValle (The Horror of Red Hook by H.P. Lovecraft) The Daughter of Doctor Moreau by Silvia Moreno-Garcia (The Island of Doctor Moreau by H.G. Wells) The Holder of the World by Bharati Mukherjee (The Scarlet Letter by Nataniel Hawthorne and the Ramayana by Valmiki) Mama Day by Gloria Naylor (The Tempest by William Shakespeare) Even in Paradise by Elizabeth Nunez (King Lear by William Shakespeare) The Girl Who Fell Beneath the Sea by Axie Oh (The Tale of Shim Ch'ŏng) Kaikeyi by Vaishnavi Patel (The Ramayana by Valmiki) The Wind Done Gone by Alice Randall (Gone With the Wind by Margaret Mitchell) My Jim by Nancy Rawles (The Adventures of Huckleberry Finn by Mark Twain) Son of a Trickster by Eden Robinson (Wee'git stories) Unforgivable Love by Sophfronia Scott (Les Liaisons Dangereuses by Pierre Choderlos de Laclos) The Chosen and the Beautiful by Nghi Vo (The Great Gatsby by F. Scott Fitzgerald) Prince of Cats by Ron Wimberly (Romeo and Juliet by William Shakespeare) Sansei and Sensibility by Karen Tei Yamashita (Various works by Jane Austen) Pride by Ibi Zoboi (Pride and Prejudice by Jane Austen) Give us feedback! Fill out the form to ask for a recommendation or suggest a genre or title for us to read! Check out our Tumblr, follow us on Twitter or Instagram, join our Facebook Group, or send us an email! Join us again on Tuesday, August 16th we'll be discussing an update on what media we've been enjoying outside of the podcast. (Oh no that's next week.) Then on Tuesday, September 6th we'll be discussing the format of Audio Book Fiction!

Parchi di Londra parte seconda. Richmond park, Kensington Gardens, Bushy Park.

Grahame. Angelina, Thomas and Cindy set out to introduce this book in its historical and literary context, as well as address a few of the challenges people may have on their first reading of The Wind in the Willows. They also discuss some other pertinent topics such as Edwardian cultural concerns, the form of this novel, the rebirth images in the opening chapters, and the echoes of this book in other literature. Cindy's 2022 Morning Time for Moms Summer Discipleship group is now open for registration. The theme this year is “Laughter and Lament.” Head over to morningtimeformoms.com to find out more and sign up! Thomas will be teaching a webinar on Napoleon Bonaparte later this month, as well as an introductory course on Russian Literature in July 2022. Learn more and register at houseofhumaneletters.com. Commonplace Quotes: There is no vice so simple but assumes/ Some mark of virtue on his outward parts. William Shakespeare, from The Merchant of Venice A boat will not answer to the rudder unless it is in motion. The poet can work upon us only as long as we are kept on the move. C. S. Lewis, from his Preface to Paradise Lost One does not argue about The Wind in the Willows. The young man gives it to the girl with whom he is in love, and, if she does not like it, asks her to return his letters. The older man tries it on his nephew, and alters his will accordingly. The book is a test of character. We can't criticize it, because it is criticizing us. But I must give you one word of warning. When you sit down to it, don't be so ridiculous as to suppose that you are sitting in judgement on my taste, or on the art of Kenneth Grahame. You are merely sitting in judgment on yourself. You may be worth: I don't know, but it is you who are on trial. A. A. Milne Sonnet to the River Otter by Samuel Taylor Coleridge Dear native brook! wild streamlet of the West! How many various-fated years have passed, What happy and what mournful hours, since last I skimmed the smooth thin stone along thy breast, Numbering its light leaps! Yet so deep impressed Sink the sweet scenes of childhood, that mine eyes I never shut amid the sunny ray, But straight with all their tints thy waters rise, Thy crossing plank, thy marge with willows grey, And bedded sand that, veined with various dyes, Gleamed through thy bright transparence! On my way, Visions of childhood! oft have ye beguiled Lone manhood's cares, yet waking fondest sighs: Ah! that once more I were a careless child! Book List: The Golden Age by Kenneth Grahame Dream Days by Kenneth Grahame The Five Children and It by Edith Nesbit Kim by Rudyard Kipling Peter Pan in Kensington Gardens by J. M. Barrie Cautionary Tales for Children by Hilaire Belloc A Little Princess by Frances Hodgson Burnett The Wonderful Wizard of Oz by L. Frank Baum Anne of Green Gables by L. M. Montgomery Our Island Story by H. E. Marshall Far From the Madding Crowd by Thomas Hardy Mary Poppins by P. L. Travers P. G. Wodehouse Leisure the Basis of Culture by Josef Pieper Jayber Crow by Wendell Berry Kenneth Grahame: A Biography by Peter Green   Support The Literary Life: Become a patron of The Literary Life podcast as part of the “Friends and Fellows Community” on Patreon, and get some amazing bonus content! Thanks for your support! Connect with Us: You can find Angelina and Thomas at HouseofHumaneLetters.com, on Instagram @angelinastanford, and on Facebook at https://www.facebook.com/ANGStanford/ Find Cindy at morningtimeformoms.com, on Instagram @cindyordoamoris and on Facebook at https://www.facebook.com/cindyrollins.net/. Check out Cindy's own Patreon page also! Follow The Literary Life on Instagram, and jump into our private Facebook group, The Literary Life Discussion Group, and let's get the book talk going! http://bit.ly/literarylifeFB

Subscribe Apple | Google | Spotify | Stitcher | iHeart   Support The Daily Gardener Buy Me A Coffee    Connect for FREE! The Friday Newsletter |  Daily Gardener Community   Historical Events National Public Gardens Week  This week marks the beginning of National Public Gardens Week (May 6-15). This celebration started in 2009 as part of the effort to bring attention to the country's public gardens. Go Public Gardens is an ongoing, evergreen Association initiative to drive the public to visit, value, and volunteer at public gardens in their area and when they travel. You can be part of the celebration by visiting a public garden this week. You can find gardens near you on the interactive Garden Map.   1781 Birth of Henri Cassini, French botanist and naturalist. Henri's second great grandfather was the famous Italian astronomer Giovanni Domenico Cassini; he discovered Jupiter's Great Red Spot and the Cassini division in Saturn's rings. Henri took a decidedly different path than his ancestors. He was the fifth generation of a family of star scholars, so Henri is often referred to as Cassini V. Henri became a lawyer, and like many professionals, botany was a hobby for Henri. His heart belonged to the sunflower family, and it is fitting that the genus Cassinia(the sunflower genus) was named in his honor by the botanist Robert Brown. Henri's work had staying power. Many of his sunflower descriptions and observations are still valid over two centuries later. Henri married his cousin and had no children. He died of cholera at 50, and he was the last of the Cassini name - and a punctuation mark on the wonderful Cassini legacy.   1807 On this day in 1807, Lewis and Clark returned a book they had borrowed from Benjamin Smith Barton. Before starting their incredible expedition, Meriwether Lewis visited Barton at his home. Meriwether left with Barton's copy of The History of Louisiana by Antoine le Page. Meriwether memorialized the gesture in the flyleaf of the book, writing: Dr. Benjamin Smith Barton was so obliging as to lend me this copy of Mons. Le Page's History of Louisiana in June 1803. It has been since conveyed by me to the Pacific ocean through the interior of North America on my late tour thither and is now returned to its proprietor by his friends and obedient servant, Meriwether Lewis. Philadelphia, May 9, 1807.   1860 Birth of James Matthew Barrie (books by this author), Scottish novelist, and playwright. James is best remembered as the creator and author of Peter Pan, and he drew inspiration from the real world's Kensington Gardens. In 1912, James commissioned Sir George Frampton to build a statue of Peter Pan in Kensington Gardens. It's been a favorite of visitors to the park ever since. Gardens and flowers were other sources of inspiration for James. The following are just a few samples of his garden inspired prose: There is almost nothing that has such a keen sense of fun as a fallen leaf. The unhappy Hook was as impotent as he was damp, and he fell forward like a cut flower. All children, except one, grow up. They soon know that they will grow up, and the way Wendy knew was this. One day when she was two years old, she was playing in a garden, and she plucked another flower and ran with it to her mother. I suppose she must have looked rather delightful, for Mrs. Darling put her hand to her heart and cried, ‘Oh, why can't you remain like this forever!' This was all that passed between them on the subject, but henceforth Wendy knew that she must grow up. You always know after you are two. Two is the beginning of the end.   James also wrote, God gave us memories that we may have roses in December.   1921 Birth of Sophia Magdalena Scholl (books about this person), German student, and anti-Nazi activist. Sophia was part of the White Rose non-violent resistance group started by her brother Hans. The two were arrested and convicted of high treason after distributing anti-war leaflets at the University of Munich. Sophia was executed by guillotine. Her last words were, “long live freedom.” Since the 1970s, Sophia has been praised and remembered for her anti-Nazi resistance work. In 2021, Sophia was commemorated on a special sterling silver collector's coin issued on her 100th birthday. It was Sophie Scholl, leader of the White Rose Movement, who said, Who would have thought it possible that a tiny little flower could preoccupy a person so completely that there simply wasn't room for any other thought.   Grow That Garden Library™ Book Recommendation Patina Living by Steve Giannetti and Brooke Giannetti This book came out in 2019, and this is The heartwarming story of how the Giannetties live and entertain in the well-designed and lushly planted gardens of their farm in Ojai, California. If you're a longtime listener of the show, you know that I recommended Steve and Brooke's second book Patina Farmjust a few weeks ago. But this is actually their third book, and it's called Patina Living, and it came out in 2019. And as the publisher says, The heartwarming story of how the Giannetties live and entertain in the well-designed and lushly planted gardens of their farm in Ojai, California. So this book is truly dedicated to the gardens there on the property. Now, I thought I'd give you a complete overview of all the Giannetti books; I think they're all fantastic. Their first book came out in 2011 and was called Patina Style. Now that book was all about their interior design. The second book, the book that I just profiled a few weeks ago, is called Patina Farm. And that's talking about basically the entire property inside and out, including the gardens. And now, this third book, Patina Living, is all about the gardens. And then, of course, there's one called Patina Homes after this one. But this book, in particular, is the one that we're talking about today, and it is Patina Living, and they don't call it Patina Gardens, essentially, because there is so much life in these gardens. There are outdoor rooms. There are kitchen gardens. There are animals. There's just so much going on outdoors for the family, which is why they chose to call it Patina Living. Now I thought it would be fun to review this power couple of Brooke Giannetti and Steve Giannetti. Brooke is a California-based interior designer. She's got her shop, and she's a blogger. And so everything that she's putting together is just so artfully done. She's a natural stylist. And then you have Steve Giannetti. He's an architect, and he works on all kinds of projects. So there's the two of them together, and they work so well together. In the introduction to Patina Living, Brooke and Steve share this incredibly heart-wrenching story of when they had to leave Patina Farm back in 2017 - five years ago when one of the California wildfires was threatening their property. And so they had to load everything up quickly, and they were prepared to say goodbye to all of it. And so here is this little excerpt from what Brooke wrote. She said, As we hurried through the now-mature grounds of Patina Farm, we were reminded of the time we had installed the new plantings that would become our outdoor rooms.  Now, five years later, the gardens looked lush and lovely, softened by the pale pink haze of the fire; but they were also quiet and lifeless. Our donkeys, Buttercup, Daisy, Blossom, and Huckleberry, were not grazing the lower fields or sleeping under the pepper trees as they normally did. The protected garden and animal barn next to my office - where our miniature pygmy goats, sisters Thelma and Louise and their best friend, Dot, and our sheep, Linen, Paisley, and Cashmere, normally lounged and played - were silent and deserted. As we headed out to our packed cars, Steve asked me if there was anything else that I wanted to take with us. - looked around at the house -a house we had spent years thoughtfully designing-and realized that all I really needed to take, the soul of our house, was already securely resting in our cars.   Isn't that touching? Later on, in the introduction, Brooke sets out her goals for this book, Patina Living. And she writes As we've shared our journey to Patina Farm, many of our readers have shared their desire to move toward an organic, nature-centered life. Some of you just want to add more gardens to your property or figure out how to have a few chickens in your side yard, while others dream of creating your version of Patina Farm, with farmanimals and a potager to grow your own food. We are writing this book for all of you, to share why we decided to embrace this lifestyle and whatwe have learned along the way. We will also introduce you to some of the wonderful people in our life who have helped us navigate the winding road of farm life. One of the important nuggets of wisdom we have learned is that there is not just one way to live. The idea of this book is to explain what works (and hasn't worked) for us and why. By sharing our journey, we hope to demystify the homestead farm lifestyle. If we city folk can do it, SO can you!   What I love about Brooke and Steve - and what they've done here - is how authentic they are and how creative they are because they approach everything from the Giannetti angle on design and functionality. Again, it's got to work for them because this is a working farm. This is a homestead property. And so, while they want things to look beautiful, they're also pragmatists. I love that mix. Now, granted, up here in Minnesota, I'm never going to have the type of climate that they enjoy in Ojai, California. I'm never going to be able to grow rosemary and lavender year-round outdoors in my garden. But again, there is so much of what Steve and Brooke do here that can be translated into new solutions no matter where you live. So if you're looking for best practices, I think you cannot go wrong with any book by Steve and Brooke Gianetti. This book is 208 pages of gardens, gardens, gardens, outdoor living, all kinds of outbuildings, and spaces for animals -  and a gorgeous potager to boot - on a high-end homestead. You can get a copy of Patina Living by Steve Giannetti and Brooke Giannetti and support the show using the Amazon link in today's show notes for around $8.   Botanic Spark 1938 Birth of Charles Simic (books by this author), Serbian American poet and former co-poetry editor of the Paris Review. He taught English and creative writing for over three decades at the University of New Hampshire.  In 1990, Charles received the Pulitzer Prize for Poetry. In 2007 he was appointed the fifteenth Poet Laureate Consultant in Poetry to the Library of Congress. Charles is one of the most compelling modern poets writing today. He once wrote, Even when I'm stretched out in my coffin, they may find me tinkering with some poem.   Here's an excerpt from his poem called In The Traffic. What if I were to ditch my car And walk away without a glance back? While drivers honk their horns As I march toward the woods, Determined, once and for all, To swap this breed of lunatics For a more benign kind who dwell In trees, long-haired and naked. I'll let the sun be my guide As I roam the countryside, stopping to chat With a flower or a butterfly, Subsisting on edible plants, I find, Glad to share my meal with deer, Or find a bear licking my face As I wake up, asking where am I? Stuck in the traffic, Mister!   And here's his very brief poem called Watermelons: Green Buddhas On the fruit stand We eat the smile And spit out the teeth.   Thanks for listening to The Daily Gardener And remember: For a happy, healthy life, garden every day.  Henri Cassini, Meriwether Lewis, James Matthew Barrie, Sophie Scholl, Patina Living, Steve Giannetti, Brooke Giannetti, Charles Simic, Benjamin Smith Barton

"second to the left and straight on till mourning"

Reading of...Peter Pan in Kensington Gardensby J.M. BarrieChapter 4Lock-out TimeRead by Sir StoneMusic playlist provided by SoundstripeSupport this podcast at — https://redcircle.com/sir-reads/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Reading of...Peter Pan in Kensington Gardensby J.M. BarrieChapter 3The Little HouseRead by Sir StoneMusic playlist provided by SoundstripeSupport this podcast at — https://redcircle.com/sir-reads/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Reading of...Peter Pan in Kensington Gardensby J.M. BarrieChapter 2The Thrush's NestRead by Sir StoneMusic playlist provided by SoundstripeSupport this podcast at — https://redcircle.com/sir-reads/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Reading of...Peter Pan in Kensington Gardensby J.M. BarrieChapter 1Peter PanRead by Sir StoneMusic playlist provided by SoundstripeSupport this podcast at — https://redcircle.com/sir-reads/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

"And the biggest and poshest shelter? I'll bet you can guess."

Ich begrüße euch zu einer weiteren Ausgabe in unserer Rubrik "Helden, Versager und andere Ikonen", in der wir uns den bekanntesten fiktiven Charakteren der Popkultur widmen. Wenn ihr euch für die anderen Sendungen in dieser Rubrik interessiert, findet ihr sie alle auf phantastikon.de versammelt. Heute geht es um Peter Pan. Zweifellos ist die Geschichte von Peter Pan, der mit Wendy und ihren Brüdern Nimmerland erkundet, eine der populärsten der Welt. Die Geschichte, die dieser Geschichte vorausging und oft übersehen wird, heißt jedoch Peter Pan in Kensington Gardens. Musik von Aleksandr Shamaluev. Folge direkt herunterladen

Stai ascoltando un estratto gratuito di Ninja PRO, la selezione quotidiana di notizie per i professionisti del digital business. Con Ninja PRO puoi avere ogni giorno marketing insight, social media update, tech news, business events e una selezione di articoli di approfondimento dagli esperti della Redazione Ninja. Vai su www.ninja.it/ninjapro per abbonarti al servizio.Vita decentralizzata. Airbnb sta raddoppiando il suo sforzo di marketing come destinazione per il "work-from-anywhere". Stavolta a metterci la faccia è lo stesso CEO Brian Chesky, che ha annunciato su Twitter che nei prossimi mesi salterà di città in città ogni due settimane, con l'obiettivo di "migliorare l'esperienza per le persone che ora possono vivere ovunque". Una mostra d'arte in Fortnite. L'artista americano KAWS sta inaugurando una mostra ai Kensington Gardens di Londra e una replica quasi esatta all'interno di Fortnite. Si tratta della prima grande galleria d'arte ad essere ospitata in un mondo di gioco virtuale. Obiettivo: introdurre una generazione di giovani alle belle arti.Tencent può leggere i volti dei giocatori. La Cina è determinata a fare in modo che i bambini giochino il meno possibile ai videogiochi. Pechino sta per imporre un limite di 14 ore di gioco a settimana per i ragazzi sotto i 18 anni, e Tencent (il più grande sviluppatore di giochi del mondo) sta introducendo un sistema di riconoscimento facciale per assicurarsi che i minori non stiano infrangendo le regole o accedendo utilizzando le credenziali di una persona più grande quando giocano online.

In this episode, recorded for National Tree Week, Community Learning Officer Laura Ashfield talks to tree expert and arboriculturist Greg Packman whose knowledge of and passion for trees is unmatched. Together they chat about his favourite trees in the park, finding out what makes them special and also uncover some of the traditional myths and folklore that surrounds some of our most beloved tree species. About The Royal Parks: The Royal Parks is the charity that exists to make sure London's eight historic royal parks will always be there to enrich the lives of local residents and visitors to London. The charity looks after eight of London's largest open spaces: Hyde Park, The Green Park, Richmond Park, Greenwich Park, St James's Park, Bushy Park, The Regent's Park and Primrose Hill, and Kensington Gardens.  For more information visit www.royalparks.org.uk Follow The Royal Parks on social media:Twitter @TheRoyalParksFacebook @TheRoyalParksLondon Instagram @TheRoyalParksSupport the show:https://www.royalparks.org.uk/support-the-parksSupport the show (https://www.royalparks.org.uk/support-the-parks)

Come join us at the 2022 Wichita Business Expo at Century II on Thursday, September 29!  This is the premiere business-to-business trade show in Wichita.  No matter what you are looking for, you will find it at the Expo! Learn more now!When one thinks of dynamic and evolving industries, funeral services does not immediately come to mind.  However, Ashley Cozine is continuously looking for opportunities to innovate with the Cozine Memorial Group and he shares those developments with hosts Don and Ebony.  On this episode we discuss: The origins of the longtime family-run business Finding unexpected opportunities to expand and diversify The real competition that Cozine faces Running building projects during the middle of a pandemic How social media fits into the business climate Only having one shot to please your customers Learn more about Cozine Memorial Group:http://www.cozine.comFacebook ProfileInstagram ProfileTwitter ProfileLinkedIn ProfileCozine Memorial Group's tradition of providing funeral services to the families of Wichita, Kansas and the surrounding communities began in 1913. Since that time, they have continued to expand our offerings and raise the bar of funeral service in our community and across the country.Broadway Mortuary and Kensington Gardens have earned a reputation for caring, compassionate service with unsurpassed professionalism and attention to detail…making Cozine Memorial Group the leading choice among funeral, cremation, and cemetery providers in Wichita!Their commitment to providing funeral and memorial service excellence to families like yours has been recognized on a national level. They are the only mortuary in Wichita to have been inducted into the National Funeral Directors Association's Hall of Excellence. This achievement recognizes the top 2% of funeral homes in the nation for outstanding services to families, commitment to the community and dedication to upholding the highest ethical and professional standards.Continuing this legacy of service excellence while also redefining funeral service, they are excited to announce that our new Cozine Life Events Center is currently under construction and set to open in 2021. This new facility will set the standard for funeral service and provide families with unmatched options and hospitality as they honor, celebrate, and remember the life of their loved one.Other Resources:Getting to Know Ashley Cozine (article)Broadway Mortuary Owners have Unique Plan for the Future (article) Thanks for listening, be sure to subscribe and leave us a review! Join the Wichita Regional Chamber of Commerce! This podcast is brought to you by the Wichita Regional Chamber of Commerce and is powered by Evergy.  To send feedback on this show and/or send suggestions for future guests or topics please e-mail communications@wichitachamber.org. This show is part of the ICT Podcast Network.  For more information visit ictpod.net

Time for a slightly different 'A View on Access', as normally we would be heading to the theatre, but today we're off to a new immersive Art Exhibition.  Tim Calvert tells us all about Van Gogh Alive, which was just ended a spell in the Birmingham Hippodrome, can currently be enjoyed in Kensington Gardens in London, and later this year will be taking residency at MediaCity UK, in the Salford Quays. Having dazzled over 8 million visitors in 70 cities worldwide, the most visited immersive, multi-sensory experience in the world has made its hotly anticipated debut in the heart of one of London's most beautiful Royal Parks for a four month run. Hosted within a stunning, purpose-built venue in Kensington Gardens (opposite the Royal Albert Hall) from June to September, this Covid-safe and family-friendly experience is anticipated to become London's biggest visitor attraction this summer. For more details on those Audio Described tours for Van Gogh Alive, head over to vangoghaliveuk.com/london/access/ AVOA is written, presented and produced by Tim Calvert of Calvert Creative Concepts for RNIB Connect Radio and The Audio Description Association. For more information or to get involved email aviewonaccess@gmail.com

In this summer special, Learning Manager and music fan Richard Pering takes a look at the amazing concerts which have taken place in Hyde Park over the years. From Pink Floyd and The Rolling Stones in the 1960's, all the way up to the last British Summer Time in 2019, before the 2020 and 2021 gigs were cancelled due to the pandemic.Joining him on his musical quest is someone who knows more than a little about how to host the world's biggest bands, Jess Chambers, Events Communications Manager for The Royal Parks. Jess takes us behind the scenes look at these events, the history of how they came to be held here, and what it takes to make them happen, as well as why she can sometimes be found back stage, other times walking through the streets around the park to see what she can hear...About The Royal Parks: The Royal Parks is the charity that exists to make sure London's eight historic royal parks will always be there to enrich the lives of local residents and visitors to London. The charity looks after eight of London's largest open spaces: Hyde Park, The Green Park, Richmond Park, Greenwich Park, St James's Park, Bushy Park, The Regent's Park and Primrose Hill, and Kensington Gardens.  For more information visit www.royalparks.org.uk Follow The Royal Parks on social media:Twitter @TheRoyalParksFacebook @TheRoyalParksLondon Instagram @TheRoyalParksSupport the show:https://www.royalparks.org.uk/support-the-parksSupport the show (https://www.royalparks.org.uk/support-the-parks)

Peter Pan in Kensington Gardens - J. M. Barrie - Book 4 Title: Peter Pan in Kensington Gardens Overview: Peter Pan in Kensington Gardens is a novel by J. M. Barrie, illustrated by Arthur Rackham, and published by Hodder & Stoughton in late November or early December 1906; it is one of four major literary works by Barrie featuring the widely known literary character he created, Peter Pan. When he is seven days old, Peter Pan flies away from his mother (forgetting that he is no longer a bird and therefore cannot fly), comes to live in Kensington Gardens, and acquires a goat. Most of the text originally appeared in chapters 13–18 of Barrie's 1902 novel The Little White Bird. Published: 1906 Series: Peter Pan Series, Novels Series, Pan #3 Author: J. M. Barrie Genre: Fairytale Fantasy, Fictional Diary, Novel for Adult Readers, Action & Adventure Episode: Peter Pan in Kensington Gardens - J. M. Barrie - Book 4 Part: 1 of 1 Length Part: 2:25:03 Book: 4 Length Book: 2:25:03 Episodes: 1 - 6 of 6 Predecessor: Peter Pan Successor: Peter and Wendy Narrator: Peter Eastman Memorium: Lucy Burgoyne (1950 - 2014) Language: English Edition: Unabridged Audiobook Keywords: adventure, travel, hero, struggle, danger, camaraderie, eternal youth, children, rescue, fantasy, magical, JMBarrie Hashtags: #freeaudiobooks #audiobook #mustread #readingbooks #audiblebooks #favoritebooks #free #booklist #audible #freeaudiobook #adventure #travel #hero #struggle #danger #camaraderie #eternal #youth #children #rescue #fantasy #magical #JMBarrie Credits: All LibriVox Recordings are in the Public Domain. Wikipedia (c) Attribution-ShareAlike 3.0 Unported License. WOMBO Dream. Peter Eastman. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/free-audiobooks/message Support this podcast: https://anchor.fm/free-audiobooks/support

The Little White Bird - Peter Pan - J. M. Barrie - Book 1, Part 2 Title: The Little White Bird Overview: The Little White Bird is a novel by the Scottish writer J. M. Barrie, ranging in tone from fantasy and whimsy to social comedy with dark, aggressive undertones. It was published in November 1902, by Hodder & Stoughton in the UK and Scribner's in the US (and the latter also published it serially in the monthly Scribner's Magazine from August to November). The book attained prominence and longevity thanks to several chapters written in a softer tone than the rest of the book, which introduced the character and mythology of Peter Pan. In 1906, those chapters were published separately as a children's book, Peter Pan in Kensington Gardens. The Peter Pan story began as one chapter and grew to an "elaborate book-within-a-book" of more than one hundred pages during the four years Barrie worked on The Little White Bird. "A children's book, sharp social commentary, and a sad psychological thriller about a man's search for a sense of belonging. All in one amazing and lyrical collection. This is the first book in which Peter Pan starts to appear. His adventure in Kensington Gardens is first narrated here. Other than that, it offers a magical portrait of contemporary London, and a realistic tale of a family to which every one of us could have belonged." The complete book has also been published under the title The Little White Bird, or Adventures in Kensington Gardens. Published: 1902 Series: Peter Pan Series, Novels Series, Pan #1 Author: J. M. Barrie Genre: Fairytale Fantasy, Fictional Diary, Novel for Adult Readers, Action & Adventure Episode: The Little White Bird - Peter Pan - J. M. Barrie - Book 1, Part 2 Part: 2 of 2 Length Part: 4:12:27 Book: 1 Length Book: 7:25:34 Episodes: 14 - 26 of 26 Successor: Peter Pan Narrator: Collaborative Language: English Edition: Unabridged Audiobook Keywords: adventure, travel, hero, struggle, danger, camaraderie, eternal youth, children, rescue, fantasy, magical, JMBarrie Hashtags: #freeaudiobooks #audiobook #mustread #readingbooks #audiblebooks #favoritebooks #free #booklist #audible #freeaudiobook #adventure #travel #hero #struggle #danger #camaraderie #eternal #youth #children #rescue #fantasy #magical #JMBarrie Credits: All LibriVox Recordings are in the Public Domain. Wikipedia (c) Attribution-ShareAlike 3.0 Unported License. WOMBO Dream. Stav Nisser. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/free-audiobooks/message Support this podcast: https://anchor.fm/free-audiobooks/support

The Little White Bird - Peter Pan - J. M. Barrie - Book 1, Part 1 Title: The Little White Bird Overview: The Little White Bird is a novel by the Scottish writer J. M. Barrie, ranging in tone from fantasy and whimsy to social comedy with dark, aggressive undertones. It was published in November 1902, by Hodder & Stoughton in the UK and Scribner's in the US (and the latter also published it serially in the monthly Scribner's Magazine from August to November). The book attained prominence and longevity thanks to several chapters written in a softer tone than the rest of the book, which introduced the character and mythology of Peter Pan. In 1906, those chapters were published separately as a children's book, Peter Pan in Kensington Gardens. The Peter Pan story began as one chapter and grew to an "elaborate book-within-a-book" of more than one hundred pages during the four years Barrie worked on The Little White Bird. "A children's book, sharp social commentary, and a sad psychological thriller about a man's search for a sense of belonging. All in one amazing and lyrical collection. This is the first book in which Peter Pan starts to appear. His adventure in Kensington Gardens is first narrated here. Other than that, it offers a magical portrait of contemporary London, and a realistic tale of a family to which every one of us could have belonged." The complete book has also been published under the title The Little White Bird, or Adventures in Kensington Gardens. Published: 1902 Series: Peter Pan Series, Novels Series, Pan #1 Author: J. M. Barrie Genre: Fairytale Fantasy, Fictional Diary, Novel for Adult Readers, Action & Adventure Episode: The Little White Bird - Peter Pan - J. M. Barrie - Book 1, Part 1 Part: 1 of 2 Length Part: 3:13:03 Book: 1 Length Book: 7:25:34 Episodes: 1 - 13 of 26 Successor: Peter Pan Narrator: Collaborative Language: English Edition: Unabridged Audiobook Keywords: adventure, travel, hero, struggle, danger, camaraderie, eternal youth, children, rescue, fantasy, magical, JMBarrie Hashtags: #freeaudiobooks #audiobook #mustread #readingbooks #audiblebooks #favoritebooks #free #booklist #audible #freeaudiobook #adventure #travel #hero #struggle #danger #camaraderie #eternal #youth #children #rescue #fantasy #magical #JMBarrie Credits: All LibriVox Recordings are in the Public Domain. Wikipedia (c) Attribution-ShareAlike 3.0 Unported License. WOMBO Dream. Stav Nisser. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/free-audiobooks/message Support this podcast: https://anchor.fm/free-audiobooks/support

We catch up with former head teacher Roger Leighton about what's going on in schools. Plus, we cross live to Kensington Gardens for a special travel update with Simon Calder. And today's homeschooling features Kara Gammell teaching children how to save money with three jars. See acast.com/privacy for privacy and opt-out information.

During the last 47 years Richard Young has photographed some the most famous faces in the world from Royalty such as Princess Diana, Prince Charles and The Queen, to Rock and Roll stars including Freddie Mercury, Michael Jackson, Paul McCartney Joni Mitchell to World Leaders such as Nelson Mandela. In fact, Richard can claim to have had breakfast with Nelson Mandela, lunch with The Dalai Lama and Dinner with Fidel Castro. In this access all areas interview, Richard shares his passion for his career that has taken him all over the world. But he now most enjoys walking through Kensington Gardens and Hyde Park on his way to work at his Gallery on Holland Street, Kensington W8. Subscribe, listen & enjoy Thank you for listening and remember to keep supporting your local businesses. richardyounggallery.co.uk @richardyounggallery Email Us - podcast@kensingtonbusinessforum.co.uk Host Selma Anderson - andersonassociates.london Host Luis Guimaraes - nestseekers.com/agent/luis-guimaraes Presenter & Producer Stephen Chandler - instagram.com/stevechandlervo/ Kensington Business Forum kensingtonbusinessforum.co.uk #RichardYoung #Photography #PrincessDiana #FreddieMercury #Queen #DavidBowie #TheWho #KateMoss #JohnnyDepp #MickJagger #TheRollingStones #JerryHall #LiveAid #MarcBolan #TRex #TheBeatles #BobDylan #AdamFaith #BillyFury #NelsonMandela #VanMorrison #TheDalaiLama #FidelCastro #EltonJohn #PhilCollins #RonnieWood #BillyZane #JimmyPage #LedZeppelin #ElleMacPherson #MarvinGaye #Hollywood #VanityFair #Oscars #JoniMitchell #Biba #GlenMatlock #MichaelJackson

Translator Will Vanderhyden joins Chad and Brian to provide an overview of Rodrigo Fresán's work--especially The Invented Part. They discuss some of his earlier works (including Kensington Gardens, which is available in an English translation), different pop culture touchstones running throughout his oeuvre, related authors, and ways to approach The Invented Part.   They also talk a bit about the schedule and the future Two Month Review podcasts. The entire reading schedule is listed below, but for the next episode (June 1st), Chad and Brian will be joined by bookseller and Best Translated Book Award just Jeremy Garber to talk about "The Real Character," pages 1-45.   Here's the complete rundown of Two Month Review podcasts for The Invented Part: June 1: "The Real Character" (1-45) June 8: "Place Where the Sea Ends" (Part 1) (46-98) June 15: "Place Where the Sea Ends" (Parts 2) (99-207) June 22: "Place Where the Sea Ends" (Parts 3) (208-229) June 29: "A Few Things You Happen to Think About" (230-300) July 6: "Many Fetes" (301-360) July 13: "Life After People" (361-403) July 20: "Meanwhile, Once Again" (404-439) July 27: "The Imaginary Person" (440-547)   In addition to these weekly podcasts, there will be some bonus posts here on Three Percent, and you can share your opinions and questions at the official GoodReads Group.    Additionally, we are offering a 20% discount on orders of The Invented Part from the Open Letter website. Just enter 2MONTH in the discount field at checkout. Copies are on hand and will ship out immediately. They're also available at better bookstores everywhere.   Follow Open Letter, Chad Post, and Brian Wood on Twitter for more thoughts and information about upcoming guests.   And you can find all Two Month Review posts by clicking here.   The music for the first season of Two Month Review is "Big Sky" by The Kinks.    And if you like the podcast, tell a friend and rate us or leave a review on iTunes!